Treatment of autoimmunity using personalized mesenchymal stem cells
By dedifferentiating patient cells into pluripotent stem cells, inserting autoantigens, and differentiating them into mesenchymal stem cells, the method addresses the limitations of current autoimmune treatments by specifically inhibiting autoreactive responses and promoting immune tolerance, enhancing therapeutic efficacy.
Patent Information
- Application Number
- PCT/US2026/026881
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for autoimmune disorders, such as rheumatoid arthritis, are limited in their ability to specifically inhibit autoreactive responses while preserving other immune functions, leading to potential side effects and incomplete disease control.
A method involving dedifferentiation of patient-derived cells into pluripotent stem cells, insertion of autoantigens and tolerance-promoting molecules, and differentiation into mesenchymal stem cells for administration, which can modulate immune responses and promote tolerance.
This approach effectively targets autoreactive responses, reducing autoimmune symptoms while maintaining immune integrity, offering a more targeted and safer therapeutic option.
Smart Images

Figure US2026026881_12112026_PF_FP_ABST
Abstract
Description
Immorta-TOAUPMSC-PCTTREATMENT OF AUTOIMMUNITY USING PERSONALIZED MESENCHYMAL STEM CELLSCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims benefit of United States Provisional Application Serial No. 63 / 800,866, filed on May 6, 2025, entitled “Treatment of Autoimmunity Using Personalized Mesenchymal Stem Cells”, the contents of which are incorporated herein by reference in its entirety.FIELD OF THE INVENTION
[0002] The invention herein relates to the treat of autoimmune disorders through the administration of progenitor cells such as mesenchymal stem cells.BACKGROUND OF THE INVENTION
[0003] New methods of treating autoimmune disorders are needed. A goal of the invention herein is to use progenitor cells such as mesenchymal stem cells to treat autoimmune disorders.
[0004] Rheumatoid arthritis (RA) is a chronic inflammatory disorder affecting approximately 0.5-1% of the global population [1], characterized by immune-mediated synovial inflammation and joint deterioration. Additionally, numerous extra- articular manifestations have been reported including accelerated atherosclerosis, heart attacks, pericarditis, lung issues, and conditions associated with systemic inflammation [2],
[0005] In general, because of the critical role of inflammation in the pathology of RA, patients are usually started on NSAIDS, however more recent practice has been concurrent initiation of disease modifying antirheumatic drugs (DMARDs). These agents are slow acting but have been demonstrated to inhibit radiological progression of RA. Such agents typically include: 1) hydroxychloroquine, which acts in part as a toll like receptor (TLR) 7 / 9 antagonist [3], thus decreasing innate immune activation [4]; 2) Leflunomide, an antimetabolite that inhibits pyrimidine synthesis and protein tyrosine kinase activity [5], which results in suppression of T cell responses [6], inhibition of dendritic cell (DC) activation [7] and augmentation of T regulatory (Treg) activity [8-10]; 3) Injectable gold compounds such as auranofin which directly or through metabolites such as dicyanogold (i) have been demonstrated to inhibit T cell and antigen presenting cell activation [11, 12], as well as cause Th2 deviation
[0013] ; 4) Sulfasalazine, was used since 1950, acts primarily through inhibition of cycloxygenase and lipoxygenase
[0014] ; and 5) Methotrexate, anImmorta-TOAUPMSC-PCTantifolate that inhibits T cell activation and proliferation, that has been one of the golden standards for RA
[0015] , Typically combinations of DMARDs with glucocorticoids are used, or alternatively pulse of high dose glucocorticoids are administered to cause a general inhibition of inflammation
[0016] ,
[0006] The TNF-alpha targeting agents, Remicade, Enbrel, and Humira, sometimes referred to as “biological DMARDs” are used primarily after response to conventional DMARDs has failed
[0017] , Although improvement in quality of life has occurred as a result of biological DMARDs, substantial progress remains to be made. For example, TNF-alpha blockers have been associated with reactivation of infectious disease, autoantibody formation and the possibility of increased lymphoma risk [ 18-20]. Thus, to date, one of the major limitations to RA therapy has been lack of ability to specifically inhibit autoreactive responses while allowing other immune components to remain intact.SUMMARY OF THE INVENTION
[0007] A summary of the invention is provided below with respect to the following numbered aspects.
[0008] 1. A method of treating an autoimmune condition comprising the steps of: a) obtaining a cell population from said patient suffering from said autoimmune condition; b) dedifferentiating said cell population into a pluripotent state; c) inserting one or more autoantigens into said cell in said pluripotent state; d) optionally inserting one or more tolerance promoting molecules into said cell in said pluripotent state; e) differentiating said pluripotent stem cell into a mesenchymal stem cell; and f) administering said mesenchymal stem cell into a patient in need of treatment.
[0009] 2. The method of aspect 1, wherein said autoimmune disease is selected from a group of autoimmune diseases comprising: The known human autoimmune conditions include: a) Acute disseminated encephalomyelitis (ADEM); b) Addison’s disease; c) Alopecia areata; d) Ankylosing spondylitis; e) Anti-GBM (Goodpasture’s) disease; f) Anti-NMDA receptor encephalitis; g) Antiphospholipid syndrome (APS); h) Autoimmune angioedema; i) Autoimmune dysautonomia; j) Autoimmune encephalitis; k) Autoimmune gastritis; 1) Autoimmune hepatitis; m) Autoimmune inner ear disease (AIED); n) Autoimmune lymphoproliferative syndrome (ALPS); o) Autoimmune myocarditis; p) Autoimmune oophoritis; q) Autoimmune orchitis; r) Autoimmune pancreatitis; s) Autoimmune polyendocrine syndrome (APS) type 1; t) Autoimmune polyendocrineImmorta-TOAUPMSC-PCTsyndrome (APS) type 2; u) Autoimmune progesterone dermatitis; v) Autoimmune retinopathy; w) Autoimmune thrombocytopenic purpura (ITP); x) Autoimmune thyroiditis (Hashimoto’s thyroiditis); y) Autoimmune urticaria; z) Autoimmune uveitis; aa) Balo disease; ab) Behcet’s disease; ac) Bullous pemphigoid; ad) Castleman disease; ae) Celiac disease; af) Chronic inflammatory demyelinating polyneuropathy (CIDP); ag) Chronic recurrent multifocal osteomyelitis (CRMO); ah) Churg-Strauss syndrome (Eosinophilic granulomatosis with polyangiitis, EGPA); ai) Cicatricial pemphigoid; aj) Cogan’s syndrome; ak) Cold agglutinin disease; al) CREST syndrome (limited scleroderma); am) Crohn’s disease; an) Dermatitis herpetiformis; ao) Dermatomyositis; ap) Devic’s disease (Neuromyelitis optica); aq) Discoid lupus; ar) Dressier’s syndrome; as) Eosinophilic esophagitis; at) Eosinophilic fasciitis; au) Erythema nodosum; av) Evans syndrome; aw) Fibrosing alveolitis; ax) Giant cell arteritis (Temporal arteritis); ay) Giant cell myocarditis; az) Glomerulonephritis (autoimmune); ba) Graves’ disease; bb) Guillain-Barre syndrome (GBS); be) Hemolytic anemia (autoimmune); bd) Henoch-Schonlein purpura (IgA vasculitis); be) Hypogammaglobulinemia; bf) Idiopathic inflammatory demyelinating diseases; bg) IgG4-related sclerosing disease; bh) Immune-mediated necrotizing myopathy; bi) Inclusion body myositis; bj) Interstitial cystitis (autoimmune); bk) Juvenile arthritis; bl) Juvenile dermatomyositis; bm) Kawasaki disease; bn) Lambert-Eaton myasthenic syndrome; bo) Leukocytoclastic vasculitis; bp) Lichen planus; bq) Lichen sclerosus; br) Linear IgA disease (LAD); bs) Lupus nephritis; bt) Lymphocytic colitis; bu) Meniere’s disease; bv) Microscopic polyangiitis (MPA); bw) Mixed connective tissue disease (MCTD); bx) Mooren’s ulcer; by) Morphea; bz) Multiple sclerosis (MS); ca) Myasthenia gravis; cb) Myositis; cc) Narcolepsy (autoimmune); cd) Neuromyelitis optica spectrum disorder (NMOSD); ce) Palindromic rheumatism; cf) PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections); eg) Paraneoplastic cerebellar degeneration; ch) Paroxysmal nocturnal hemoglobinuria (PNH); ci) Parry-Romberg syndrome; cj) Pars planitis; ck) Parsonage-Turner syndrome; cl) Pemphigus vulgaris; cm) Peripheral neuropathy (autoimmune); cn) Perivenous encephalomyelitis; co) Pernicious anemia; cp) POEMS syndrome; cq) Polyarteritis nodosa; cr) Polymyalgia rheumatica; cs) Polymyositis; ct) Postmyocardial infarction syndrome; cu) Postpericardiotomy syndrome; cv) Primary biliary cholangitis (PBC); cw) Primary sclerosing cholangitis; ex) Progressive inflammatory neuropathy; cy) Psoriasis; cz) Psoriatic arthritis; da) Pure red cell aplasia; db) Pyoderma gangrenosum; de) Raynaud’s phenomenon (autoimmune); dd) Reactive arthritis; de) Relapsing polychondritis; df)Immorta-TOAUPMSC-PCTRestless legs syndrome (autoimmune); dg) Retroperitoneal fibrosis; dh) Rheumatic fever; di) Rheumatoid arthritis (RA); dj) Sarcoidosis; dk) Schmidt syndrome; dl) Scleritis; dm) Scleroderma (systemic sclerosis); dn) Sjogren’s syndrome; do) Sperm and testicular autoimmunity; dp) Stiff person syndrome; dq) Subacute bacterial endocarditis (autoimmune); dr) Susac’s syndrome; ds) Sympathetic ophthalmia; dt) Systemic lupus erythematosus (SLE); du) Takayasu’s arteritis; dv) Thrombocytopenia (autoimmune); dw) Tolosa-Hunt syndrome; dx) Transverse myelitis; dy) Type 1 diabetes; dz) Ulcerative colitis; ea) Undifferentiated connective tissue disease (UCTD); eb) Urticarial vasculitis; ec) Vasculitis; ed) Vitiligo; ee) Vogt-Koyanagi-Harada disease; ef) Warm autoimmune hemolytic anemia; eg) Wegener’s granulomatosis (Granulomatosis with polyangiitis, GPA).
[0010] 3. The method of aspect 1, wherein said cell population is selected from a group of cells comprising of: a) Adipocyte (fat cell); b) Alpha cell (pancreatic); c) Ameloblast; d) Astrocyte; e) B cell (B lymphocyte); f) Basal cell (epidermal); g) Beta cell (pancreatic); h) Bipolar cell (retinal); i) Cardiac muscle cell (cardiomyocyte); j) Chondrocyte; k) Chromaffin cell; 1) Ciliated epithelial cell; m) Clara cell (club cell); n) Cone cell (photoreceptor); o) Dendritic cell; p) Delta cell (pancreatic); q) Endothelial cell; r) Enterocyte; s) Eosinophil; t) Erythrocyte (red blood cell); u) Fibroblast; v) Follicular cell (thyroid); w) Gamma-delta T cell; x) Ganglion cell (retinal); y) Goblet cell; z) Granulosa cell; aa) Hepatocyte; ab) Horizontal cell (retinal); ac) Intercalated cell (kidney); ad) Interneuron; ae) Islet cell (pancreatic, general); af) Keratinocyte; ag) Kupffer cell; ah) Langerhans cell; ai) Leydig cell; aj) Macrophage; ak) Mast cell; al) Megakaryocyte; am) Melanocyte; an) Merkel cell; ao) Microglia; ap) Monocyte; aq) Motor neuron; ar) Mucussecreting cell; as) Myelin cell (Schwann cell / oligodendrocyte); at) Myocyte (skeletal muscle cell); au) Natural killer (NK) cell; av) Neutrophil; aw) Odontoblast; ax) Oligodendrocyte; ay) Osteoblast; az) Osteoclast; ba) Osteocyte; bb) Paneth cell; be) Parafollicular cell (C cell, thyroid); bd) Parietal cell (stomach); be) Pericyte; bf) Pneumocyte type I; bg) Pneumocyte type II; bh) Podocyte; bi) PP cell (pancreatic polypeptide cell); bj) Purkinje cell (cerebellar); bk) Pyramidal cell (neuronal); bl) Regulatory T cell (Treg); bm) Rod cell (photoreceptor); bn) Satellite cell (muscle); bo) Schwann cell; bp) Sebocyte; bq) Sertoli cell; br) Smooth muscle cell; bs) Spermatocyte; bt) Squamous epithelial cell; bu) Stellate cell (hepatic); bv) Stromal cell; bw) T helper cell; bx) T cytotoxic cell; by) Theca cell; bz) Trophoblast; ca) Type A cell (synoviocyte); cb) TypeImmorta-TOAUPMSC-PCTB cell (synoviocyte); cc) Vascular endothelial cell; cd) Zymogenic cell (chief cell, stomach).
[0011] 4. The method of aspect 3, wherein said cell is a sertoli cell.
[0012] 5. The method of aspect 3, wherein said cell is a monocyte.
[0013] 6. The method of aspect 3, wherein said cell is a B cell.
[0014] 7. The method of aspect 3, wherein said cell is a T cell.
[0015] 8. The method of aspect 3, wherein said cell is a NKT cell.
[0016] 9. The method of aspect 3, wherein said cell is an astrocyte.
[0017] 10. The method of aspect 4, wherein said Sertoli cell is selected based on expression of CD56.
[0018] 11. The method of aspect 4, wherein said Sertoli cell is selected based on expression of CD95.
[0019] 12. The method of aspect 4, wherein said Sertoli cell is selected based on expression of stem cell factor receptor.
[0020] 13. The method of aspect 4, wherein said Sertoli cell is selected based on expression of c-met.
[0021] 14. A method for dedifferentiating the cells of aspect 1 into pluripotent stem cells, comprising:
[0022] (a) contacting the cells with a reprogramming composition comprising at least one agent capable of inducing pluripotency; and
[0023] (b) culturing the cells under conditions effective to generate pluripotent stem cells.
[0024] 15. The method of aspect 14, wherein the reprogramming composition comprises at least one transcription factor selected from the group consisting of OCT4, SOX2, KLF4, c-MYC, NANOG, and LIN28.
[0025] 16. The method of aspect 15, wherein the reprogramming composition comprises OCT4, SOX2, KLF4, and c-MYC.
[0026] 17. The method of aspect 15, wherein the reprogramming composition comprises OCT4, SOX2, NANOG, and LIN28.
[0027] 18. The method of aspect 15, wherein the transcription factor is introduced as a nucleic acid encoding the transcription factor.
[0028] 19. The method of aspect 18, wherein the nucleic acid is a plasmid DNA.
[0029] 20. The method of aspect 18, wherein the nucleic acid is an mRNA molecule.Immorta-TOAUPMSC-PCT
[0030] 21. The method of aspect 15, wherein the transcription factor is introduced as a recombinant protein.
[0031] 22. The method of aspect 14, wherein the reprogramming composition is delivered via a viral vector.
[0032] 23. The method of aspect 22, wherein the viral vector is a lentiviral vector.
[0033] 24. The method of aspect 22, wherein the viral vector is a sendai virus vector.
[0034] 25. The method of aspect 14, wherein the reprogramming composition is delivered via a non-viral delivery system.
[0035] 26. The method of aspect 25, wherein the non-viral delivery system is selected from the group consisting of electroporation, lipid-based transfection, and polymer-based nanoparticles.
[0036] 27. The method of aspect 14, wherein the reprogramming composition comprises a small molecule reprogramming enhancer.
[0037] 28. The method of aspect 27, wherein the small molecule reprogramming enhancer is selected from the group consisting of valproic acid, CHIR99021, PD0325901, and SB431542.
[0038] 29. The method of aspect 27, wherein the small molecule reprogramming enhancer comprises a combination of CHIR99021 and PD0325901.
[0039] 30. The method of aspect 14, wherein the culturing conditions comprise a chemically defined medium.
[0040] 31. The method of aspect 30, wherein the chemically defined medium is supplemented with leukemia inhibitory factor (LIF) or basic fibroblast growth factor (bFGF).
[0041] 32. The method of aspect 14, wherein the culturing conditions comprise a feeder-free system.
[0042] 33. The method of aspect 14, wherein the culturing conditions comprise a feeder layer of inactivated fibroblasts.
[0043] 34. The method of aspect 14, wherein the culturing conditions comprise an oxygen concentration of about 2% to 5%.
[0044] 35. The method of aspect 14, wherein the culturing is performed for about 10 to 30 days.
[0045] 36. The method of aspect 14, wherein the pluripotent stem cells express at least one marker selected from the group consisting of SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and OCT4.Immorta-TOAUPMSC-PCT
[0046] 37. The method of aspect 14, further comprising verifying pluripotency by assessing teratoma formation in an immunocompromised animal.
[0047] 38. The method of aspect 14, wherein the cells of aspect 1 are human fibroblasts.
[0048] 39. The method of aspect 14, wherein the cells of aspect 1 are human peripheral blood cells.
[0049] 40. The method of aspect 14, wherein the cells of aspect 1 are non-human primate somatic cells.
[0050] 41. The method of aspect 14, wherein the reprogramming composition comprises a microRNA selected from the group consisting of miR-302a, miR-302b, miR-302c, miR-302d, and miR-367.
[0051] 42. The method of aspect 14, wherein the reprogramming composition is transiently expressed in the cells.
[0052] 43. The method of aspect 14, wherein the pluripotent stem cells are substantially free of integrated exogenous DNA.
[0053] 44. The method of aspect 14, wherein the reprogramming composition is administered in a single dose.
[0054] 45. The method of aspect 14, wherein the reprogramming composition is administered in multiple doses over a period of about 2 to 7 days.
[0055] 46. The method of aspect 14, further comprising isolating the pluripotent stem cells using fluorescence-activated cell sorting based on a pluripotency marker.
[0056] 47. The method of aspect 46, wherein the pluripotency marker is TRA-1-60.
[0057] 48. The method of aspect 14, wherein the reprogramming composition comprises a CRISPR-based system to activate endogenous expression of at least one reprogramming factor.
[0058] 49. The method of aspect 48, wherein the CRISPR-based system comprises a dCas9-VP64 fusion protein.
[0059] 50. The method of aspect 14, wherein the culturing conditions comprise a synthetic substrate.
[0060] 51. The method of aspect 50, wherein the synthetic substrate comprises recombinant laminin or vitronectin.
[0061] 52. The method of aspect 14, wherein the pluripotent stem cells exhibit a karyotype indistinguishable from the cells of aspect 1.Immorta-TOAUPMSC-PCT
[0062] 53. The method of aspect 14, further comprising cryopreserving the pluripotent stem cells in a medium comprising a ROCK inhibitor.
[0063] 54. The method of aspect 53, wherein the ROCK inhibitor is Y-27632.
[0064] 55. The method of aspect 14, wherein the culturing conditions comprise a three-dimensional matrix.
[0065] 56. The method of aspect 55, wherein the three-dimensional matrix comprises a hyaluronic acid-based hydrogel.
[0066] 57. The method of aspect 14, wherein the reprogramming composition comprises a combination of small molecules sufficient to induce pluripotency without transcription factors.
[0067] 58. The method of aspect 57, wherein the combination of small molecules comprises CHIR99021, A83-01, and ascorbic acid.
[0068] 59. The method of aspect 14, further comprising validating pluripotency by single-cell RNA sequencing to detect a pluripotent gene expression signature.
[0069] 60. The method of aspect 14, wherein the pluripotent stem cells are capable of differentiating into ectoderm, mesoderm, and endoderm lineages in vitro.
[0070] 61. The method of aspect 14, wherein the cells of aspect 1 are derived from a patient with a genetic disease, and the pluripotent stem cells are used for disease modeling.
[0071] 62. The method of aspect 14, wherein the reprogramming composition is delivered using a protein transduction domain fused to a reprogramming factor.
[0072] 63. The method of aspect 14, wherein the culturing conditions comprise a temperature of about 37°C and a CO2 concentration of about 5%.
[0073] 64. The method of aspect 14, wherein the method achieves a reprogramming efficiency of at least 0.05%.
[0074] 65. The method of aspect 14, wherein the pluripotent stem cells are suitable for use in cell therapy.
[0075] 66. The method of aspect 14, wherein the reprogramming composition comprises an epigenetic modifier selected from the group consisting of BIX-01294 and RG108.
[0076] 67. The method of aspect 14, further comprising passaging the pluripotent stem cells at least once to stabilize the pluripotent state.
[0077] 68. The method of aspect 14, wherein the culturing conditions comprise a medium supplemented with insulin and transferrin.Immorta-TOAUPMSC-PCT
[0078] 69. The method of aspect 14, wherein said dedifferentiation is conducted in the presence of one or more histone deacetylase inhibitors.
[0079] 70. The method of aspect 69, wherein said histone deacetylase inhibitor is valproic acid.
[0080] 71. The method of aspect 69, wherein said histone deacetylase inhibitor is trichostatin A.
[0081] 72. The method of aspect 69, wherein said histone deacetylase inhibitor is sodium butyrate.
[0082] 73. The method of aspect 69, wherein said histone deacetylase inhibitor is suberoylanilide hydroxamic acid.
[0083] 74. The method of aspect 69, wherein said histone deacetylase inhibitor is panobinostat.
[0084] 75. The method of aspect 69, wherein said histone deacetylase inhibitor is belinostat.
[0085] 76. The method of aspect 69, wherein said histone deacetylase inhibitor is romidepsin.
[0086] 77. The method of aspect 69, wherein said histone deacetylase inhibitor is entinostat.
[0087] 78. The method of aspect 69, wherein said histone deacetylase inhibitor is mocetinostat.
[0088] 79. The method of aspect 69, wherein said histone deacetylase inhibitor is givinostat.
[0089] 80. The method of aspect 69, wherein said histone deacetylase inhibitor is quisinostat.
[0090] 81. The method of aspect 69, wherein said histone deacetylase inhibitor is resminostat.
[0091] 82. The method of aspect 69, wherein said histone deacetylase inhibitor is abexinostat.
[0092] 83. The method of aspect 69, wherein said histone deacetylase inhibitor is pracinostat.
[0093] 84. The method of aspect 69, wherein said histone deacetylase inhibitor is tacedinaline.
[0094] 85. The method of aspect 69, wherein said histone deacetylase inhibitor is CUDC-101.Immorta-TOAUPMSC-PCT
[0095] 86. The method of aspect 69, wherein said histone deacetylase inhibitor is CUDC-907.
[0096] 87. The method of aspect 69, wherein said histone deacetylase inhibitor is AR- 42.
[0097] 88. The method of aspect 69, wherein said histone deacetylase inhibitor is scriptaid.
[0098] 89. The method of aspect 69, wherein said histone deacetylase inhibitor is sodium phenylbutyrate.
[0099] 90. The method of aspect 69, wherein said histone deacetylase inhibitor is tubacin.
[0100] 91. The method of aspect 69, wherein said histone deacetylase inhibitor is tubastatin A.
[0101] 92. The method of aspect 69, wherein said histone deacetylase inhibitor is RGFP966.
[0102] 93. The method of aspect 69, wherein said histone deacetylase inhibitor is ACY-1215.
[0103] 94. The method of aspect 69, wherein said histone deacetylase inhibitor is ACY-241.
[0104] 95. The method of aspect 69, wherein said histone deacetylase inhibitor is nexturastat A.
[0105] 96. The method of aspect 69, wherein said histone deacetylase inhibitor is BRD3308.
[0106] 97. The method of aspect 69, wherein said histone deacetylase inhibitor is 4SC-202.
[0107] 98. The method of aspect 69, wherein said histone deacetylase inhibitor is LMK-235.
[0108] 99. The method of aspect 69, wherein said histone deacetylase inhibitor is BG45.
[0109] 100. The method of aspect 69, wherein said histone deacetylase inhibitor is PCI-34051.
[0110] 101. The method of aspect 69, wherein said histone deacetylase inhibitor is MC1568.
[0111] 102. The method of aspect 69, wherein said histone deacetylase inhibitor is MS-275.Immorta-TOAUPMSC-PCT
[0112] 103. The method of aspect 69, wherein said histone deacetylase inhibitor is RG2833.
[0113] 104. The method of aspect 69, wherein said histone deacetylase inhibitor is SR-4370.
[0114] 105. The method of aspect 69, wherein said histone deacetylase inhibitor is KD5170.
[0115] 106. The method of aspect 69, wherein said histone deacetylase inhibitor is CG200745.
[0116] 107. The method of aspect 69, wherein said histone deacetylase inhibitor is ITF2357.
[0117] 108. The method of aspect 69, wherein said histone deacetylase inhibitor is LAQ824.
[0118] 109. The method of aspect 69, wherein said histone deacetylase inhibitor is LBH589.
[0119] 110. The method of aspect 69, wherein said histone deacetylase inhibitor is M344.
[0120] 111. The method of aspect 69, wherein said histone deacetylase inhibitor is CI-994.
[0121] 112. The method of aspect 69, wherein said histone deacetylase inhibitor is SB939.
[0122] 113. The method of aspect 69, wherein said histone deacetylase inhibitor is CHR-3996.
[0123] 114. The method of aspect 69, wherein said histone deacetylase inhibitor is TMP195.
[0124] 115. The method of aspect 69, wherein said histone deacetylase inhibitor is HPOB.
[0125] 116. The method of aspect 69, wherein said histone deacetylase inhibitor is TAS-116.
[0126] 117. The method of aspect 69, wherein the histone deacetylase inhibitor is present in the reprogramming composition at a concentration of about 0.1 μM to 10 mM.
[0127] 118. The method of aspect 14, wherein the reprogramming composition comprises a combination of a histone deacetylase inhibitor and a DNA methyltransferase inhibitor.Immorta-TOAUPMSC-PCT
[0128] 119. The method of aspect 118, wherein the DNA methyltransferase inhibitor is 5 -azacytidine.
[0129] 120. The method of aspect 14, wherein the culturing conditions comprise a medium supplemented with a TGF-β inhibitor.
[0130] 121. The method of aspect 120, wherein the TGF-β inhibitor is A83-01.
[0131] 122. The method of aspect 14, wherein the reprogramming composition is delivered using a polycistronic vector encoding multiple reprogramming factors.
[0132] 123. The method of aspect 14, wherein the pluripotent stem cells are generated in a xeno-free culture system.
[0133] 124. The method of aspect 14, wherein the cells of aspect 1 are keratinocytes.
[0134] 125. The method of aspect 14, wherein the reprogramming composition comprises a synthetic mRNA encoding a reprogramming factor.
[0135] 126. The method of aspect 14, wherein the culturing conditions comprise a cyclic temperature shift between about 35°C and 39°C.
[0136] 127. The method of aspect 14, wherein the pluripotent stem cells are validated by bisulfite sequencing to confirm demethylation of pluripotency gene promoters.
[0137] 128. The method of aspect 14, wherein the reprogramming composition is delivered using a liposomal carrier.
[0138] 129. The method of aspect 14, wherein the pluripotent stem cells are used to generate a tissue-engineered construct.
[0139] 130. The method of aspect 14, wherein the method achieves a reprogramming efficiency of at least 0.5% when supplemented with a histone deacetylase inhibitor.
[0140] 131. The method of aspect 1, wherein said autoantigen is gene transfected into said pluripotent stem cell.
[0141] 132. The method of aspect 131, wherein said autoantigen is constitutively expressed.
[0142] 133. The method of aspect 131, wherein said autoantigen is inducibly expressed.
[0143] 134. The method of aspect 131, wherein said autoantigen is expressed upon exposure to inflammatory conditions.
[0144] 135. A method of treating autoimmunity comprising of generating a mesenchymal stem cell from a pluripotent stem cell, wherein said mesenchymal stem cell is made to express a tolerogenic molecule.Immorta-TOAUPMSC-PCT
[0145] 136. The method of aspect 135, wherein the pluripotent stem cell is a human induced pluripotent stem cell (iPSC).
[0146] 137. The method of aspect 135, wherein the mesenchymal stem cell is derived by culturing the pluripotent stem cell under mesoderm-inducing conditions followed by expansion in mesenchymal lineage media.
[0147] 138. The method of aspect 135, wherein the tolerogenic molecule is selected from the group consisting of: PD-L1, IL-10, TGF-beta, and IDO.
[0148] 139. The method of aspect 135, wherein expression of the tolerogenic molecule is achieved by genetic modification using a viral vector.
[0149] 140. The method of aspect 139, wherein the viral vector is a lentiviral or adenoviral vector.
[0150]
[0151] 141. The method of aspect 135, wherein the mesenchymal stem cell is administered to a patient suffering from an autoimmune disorder selected from the group consisting of multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes.
[0152] 142. The method of aspect 141, wherein the mesenchymal stem cell is administered intravenously or intrathecally.
[0153] 143. The method of aspect 135, wherein the mesenchymal stem cell exhibits a phenotype characterized by CD105+, CD73+, CD90+, CD45, CD34, and HLA-DR surface markers.
[0154] 144. The method of aspect 135, wherein the tolerogenic molecule is expressed under the control of a tissue-specific or inducible promoter.
[0155] 145. The method of aspect 135, wherein the mesenchymal stem cell is cocultured with immune cells to promote immune tolerance prior to administration.
[0156] 146. The method of aspect 145, wherein the immune cells are T cells or dendritic cells.
[0157] 147. The method of aspect 135, wherein the mesenchymal stem cell secretes extracellular vesicles comprising the tolerogenic molecule.
[0158] 148. The method of aspect 135, wherein the mesenchymal stem cell is cryopreserved prior to administration.
[0159] 149. The method of aspect 135, wherein the mesenchymal stem cell is further modified to reduce expression of major histocompatibility complex (MHC) molecules.Immorta-TOAUPMSC-PCT
[0160] 150. The method of aspect 135, wherein the mesenchymal stem cell is generated using a xeno-free culture system.
[0161] 151. The method of aspect 135, wherein the tolerogenic molecule is fused to a trafficking peptide for targeted delivery in vivo.
[0162] 152. The method of aspect 135, wherein the pluripotent stem cell is an embryonic stem cell.
[0163] 153. The method of aspect 135, wherein the mesenchymal stem cell is genetically modified using CRISPR / Cas9.
[0164] 154. The method of aspect 153, wherein the genetic modification enhances expression of the tolerogenic molecule.
[0165] 155. The method of aspect 135, wherein the mesenchymal stem cell is engineered to express multiple tolerogenic molecules.
[0166] 156. The method of aspect 135, wherein the tolerogenic molecule comprises a chimeric fusion protein with enhanced half-life.
[0167] 157. The method of aspect 135, wherein the mesenchymal stem cell is tested for potency prior to clinical use.
[0168] 158. The method of aspect 157, wherein potency is determined by suppression of pro-inflammatory cytokine production in vitro.
[0169] 159. The method of aspect 135, wherein the mesenchymal stem cell is administered in combination with an immunosuppressive drug.
[0170] 160. The method of aspect 135, wherein the tolerogenic molecule promotes expansion of regulatory T cells and / or B regulatory cells.
[0171] 161. The method of aspect 135, wherein the mesenchymal stem cell is encapsulated prior to administration and / or pretreated with hyperthermia prior to administration.
[0172] 162. The method of aspect 135, wherein the tolerogenic molecule is IL-35.
[0173] 163. The method of aspect 135, wherein the mesenchymal stem cell is expanded in vitro for at least 5 passages prior to administration.
[0174] 164. The method of aspect 135, wherein the tolerogenic molecule is secreted in response to inflammatory stimuli.
[0175] 165. The method of aspect 135, wherein the mesenchymal stem cell is administered to a site of inflammation and / or directed to a site of inflammation by chemotactic targeting.Immorta-TOAUPMSC-PCT
[0176] 166. The method of aspect 135, wherein the administration is repeated at intervals of 2 to 4 weeks.
[0177] 167. The method of aspect 135, wherein the tolerogenic molecule is expressed constitutively.
[0178] 168. The method of aspect 135, wherein the mesenchymal stem cell modulates antigen-presenting cell function.
[0179] 169. The method of aspect 135, wherein the mesenchymal stem cell reduces Th 17 responses.
[0180] 170. The method of aspect 135, wherein the tolerogenic molecule is an engineered cytokine variant.
[0181] 171. The method of aspect 135, wherein the mesenchymal stem cell is selected based on secretion of anti-inflammatory factors.
[0182] 172. The method of aspect 135, wherein the tolerogenic molecule is delivered using a non-viral transfection method.
[0183] 173. The method of aspect 135, wherein the mesenchymal stem cell is preconditioned with hypoxia prior to administration.
[0184]
[0185] 174. The method of aspect 135, wherein the tolerogenic molecule binds to a receptor on effector T cells to inhibit activation.
[0186] 175. The method of aspect 135, wherein the mesenchymal stem cell is derived from a clinical-grade cell line.
[0187] 176. The method of aspect 135, wherein the tolerogenic molecule is a membrane-bound ligand.
[0188] 177. The method of aspect 135, wherein the mesenchymal stem cell is characterized by reduced expression of pro -inflammatory genes.
[0189] 178. The method of aspect 135, wherein the mesenchymal stem cell expresses a chemokine receptor for homing to lymphoid tissues.
[0190] 179. The method of aspect 135, wherein the tolerogenic molecule is released via exocytosis.
[0191] 180. The method of aspect 135, wherein the mesenchymal stem cell downregulates co- stimulatory molecules on antigen-presenting cells.
[0192] 181. The method of aspect 135, wherein the mesenchymal stem cell suppresses proliferation of autoreactive T cells.Immorta-TOAUPMSC-PCT
[0193] 182. The method of aspect 135, wherein the tolerogenic molecule is coexpressed with an immune checkpoint modulator.
[0194] 183. The method of aspect 135, wherein the mesenchymal stem cell modulates the gut microbiome.
[0195] 184. The method of aspect 135, wherein the tolerogenic molecule induces anergy in effector T cells.
[0196] 185. The method of aspect 135, wherein the mesenchymal stem cell expresses a suicide gene for safety control.
[0197] 186. The method of aspect 135, wherein the tolerogenic molecule is expressed under the control of an inflammation-responsive promoter.
[0198] 187. The method of aspect 135, wherein the mesenchymal stem cell is administered into the cerebrospinal fluid.
[0199] 188. The method of aspect 135, wherein the tolerogenic molecule enhances the generation of tolerogenic dendritic cells.
[0200] 189. The method of aspect 135, wherein the mesenchymal stem cell is coadministered with a biologic targeting autoimmune pathways.
[0201]
[0202] 190. The method of aspect 135, wherein the tolerogenic molecule is localized to lipid rafts for enhanced signaling.
[0203] 191. The method of aspect 135, wherein the mesenchymal stem cell inhibits B cell activation.
[0204] 192. The method of aspect 135, wherein the tolerogenic molecule is displayed on extracellular vesicles derived from the mesenchymal stem cell.
[0205] 193. The method of aspect 135, wherein the mesenchymal stem cell is selected for high expression of immunomodulatory markers.
[0206] 194. The method of aspect 135, wherein the tolerogenic molecule downregulates expression of inflammatory cytokines.
[0207] 195. The method of aspect 135, wherein the mesenchymal stem cell is administered following lymphodepletion.
[0208] 196. The method of aspect 135, wherein the tolerogenic molecule recruits regulatory immune cells to the site of inflammation.
[0209] 197. The method of aspect 135, wherein the mesenchymal stem cell is delivered using a hydrogel scaffold.Immorta-TOAUPMSC-PCT
[0210] 198. The method of aspect 135, wherein the tolerogenic molecule disrupts antigen-specific immune responses.
[0211] 199. The method of aspect 135, wherein the mesenchymal stem cell induces peripheral immune tolerance.
[0212] 200. The method of aspect 135, wherein the tolerogenic molecule is IL-27.
[0213] 201. The method of aspect 200, wherein IL-27 is expressed under the control of a constitutive promoter in the mesenchymal stem cell
[0214] 202. The method of aspect 200, wherein IL-27 is expressed under the control of an inducible promoter responsive to inflammatory signals.
[0215] 203. The method of aspect 202, wherein the inducible promoter is activated by a small molecule administered to the subject.
[0216] 204. The method of aspect 200, wherein the mesenchymal stem cell is genetically engineered to express IL-27 using a lentiviral vector.BRIEF DESCRIPTION OF DRAWINGS
[0217] Figure 1 is a bar graph showing arthritis score of pluripotent derived MSCs (pMSCs) compared to MSCs derived from bone marrow and umbilical cord.
[0218] Figure 2 is a bar graph showing arthritis score of pluripotent derived MSCs (pMSCs) compared to pMSCs treated with IFN-gamma and IL-37.DETAILED DESCRIPTION OF THE INVENTION
[0219] In one embodiment the invention provides stimulation of tolerogenesis through administration of immaturate mesenchymal stem cells alone, or mesenchymal stem cells made to express one or more autoantigens and / or alloantigens.
[0220] In one embodiment of the invention, a method is provided for generating immature mesenchymal stem cells (MSCs) from pluripotent stem cells (PSCs), including induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs). The invention is directed toward obtaining a population of mesenchymal-lineage cells that exhibit immunomodulatory properties and are suitable for therapeutic application, including in the treatment of autoimmune diseases.
[0221] In an exemplary embodiment, the pluripotent stem cells are first expanded under feeder-free conditions on a defined matrix such as vitronectin or Matrigel in a chemically defined medium such as mTeSRl. The PSCs are cultured to reach a confluenceImmorta-TOAUPMSC-PCTof approximately 60-80% prior to induction toward the mesodermal lineage. The cells are then subjected to mesodermal induction by exposure to differentiation media containing specific growth factors, such as BMP-4, Activin A, and basic fibroblast growth factor (bFGF). In one embodiment, the mesodermal induction is carried out over a period of 48-72 hours to direct the PSCs toward a primitive streak-like phenotype.
[0222] Following mesodermal induction, the cells are transitioned to a mesenchymal induction medium comprising basal medium such as alpha-MEM or DMEM supplemented with fetal bovine serum (FBS) or a xeno-free serum substitute, along with additives including platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and insulin-like growth factor (IGF). In one embodiment, the mesenchymal induction is continued for 7 to 14 days with medium changes every 2 to 3 days. The resulting adherent cell population is monitored for morphological changes, including spindle-shaped, fibroblast-like morphology, indicative of mesenchymal commitment.
[0223] In one aspect of the invention, the immature MSCs are identified by flow cytometric analysis using surface marker expression profiles. Specifically, cells are characterized by positive expression of CD73, CD90, and CD105, and the absence of hematopoietic markers such as CD34, CD45, and HLA-DR. In another embodiment, the immature MSCs may express additional developmental markers such as CD146 and Stro-1, which are indicative of a less differentiated or perivascular phenotype.
[0224] In a further embodiment, the immature MSCs generated according to the methods disclosed herein are characterized by their functional properties, including the ability to suppress T cell proliferation in a mixed lymphocyte reaction (MLR) assay. In one aspect, the suppression is mediated through the secretion of immunomodulatory cytokines such as TGF-\u03b2, IL- 10, or prostaglandin E2 (PGE2).
[0225] In one embodiment, genetic stability of the derived MSCs is confirmed by karyotypic analysis to ensure that no chromosomal abnormalities are present. Additionally, the population doubling time and senescence-associated beta-galactosidase activity may be evaluated to ensure cellular fitness for downstream applications.
[0226] In another aspect of the invention, the immature MSCs are expanded in vitro through multiple passages, typically ranging from 3 to 6, in order to obtain sufficient quantities for therapeutic use. In one embodiment, the cells are maintained in a hypoxic environment (e.g., 2-5% O₂) during expansion to enhance their sternness and immunomodulatory function.Immorta-TOAUPMSC-PCT
[0227] In yet another embodiment, the immature MSCs may be cryopreserved in a formulation containing dimethyl sulfoxide (DMSO) and a cryoprotectant medium, and later thawed and used without loss of function. Post-thaw viability and functional assays are performed to confirm maintenance of therapeutic properties.
[0228] In one embodiment, the invention provides a protocol for the large-scale generation of clinical-grade immature MSCs using Good Manufacturing Practice (GMP)-compliant conditions. In such embodiment, the reagents used, including growth factors, media components, and plasticware, are GMP-certified, and the process is validated for reproducibility and sterility.
[0229] In a preferred embodiment, the mesenchymal induction process avoids animal-derived components and utilizes human platelet lysate or synthetic serum substitutes to support xeno-free conditions. The resulting cells are thus suitable for allogeneic transplantation and regulatory approval for clinical use.
[0230] In one variation of the invention, PSCs are first transduced with a lineagetracing reporter construct prior to differentiation. In one embodiment, a GFP or luciferase reporter is placed under the control of a mesenchymal-specific promoter such as the PDGFR-\u03b2 or Nestin promoter to track lineage commitment and ensure uniformity of the mesenchymal population.
[0231] In another embodiment, the invention further includes quality control measures involving transcriptomic profiling to assess gene expression signatures characteristic of mesenchymal precursors. In one example, the expression of genes such as TWIST 1, SNAIL, and PRRX1 is measured by quantitative PCR to confirm mesenchymal transition.
[0232] In an embodiment, the invention further comprises a step of eliminating residual undifferentiated PSCs by cell sorting or selective culture conditions to prevent teratoma formation upon transplantation. In one example, the use of surface markers such as SSEA-4 and TRA-1-60 is employed to identify and remove undifferentiated cells.
[0233] In one embodiment, the immature MSCs are cultured in three-dimensional (3D) spheroid or hydrogel-based systems to enhance their therapeutic efficacy. In one variation, the 3D culture promotes secretion of extracellular vesicles, including exosomes enriched in anti-inflammatory microRNAs.
[0234] In another embodiment, the invention includes co-culture of the immature MSCs with peripheral blood mononuclear cells (PBMCs) to induce a tolerogenic immune phenotype, wherein an increase in FoxP3+ regulatory T cells is observed.Immorta-TOAUPMSC-PCT
[0235] In one embodiment, the invention contemplates the engineering of immature MSCs to overexpress specific immunomodulatory factors, such as PD-L1 or IL-10, through transfection or viral transduction methods, enhancing their efficacy in modulating immune responses.
[0236] The invention further encompasses therapeutic compositions comprising the immature MSCs in a pharmaceutically acceptable carrier, wherein said compositions are administered intravenously, intramuscularly, or intrathecally, depending on the targeted indication.
[0237] In one embodiment of the invention, a method is provided for treating autoimmune diseases by utilizing mesenchymal stem cells (MSCs) that are pulsed with or transfected to express autoantigens relevant to the disease. The invention relates to the generation, preparation, and application of such modified MSCs, which function to induce or expand FoxP3-positive regulatory T (Treg) cells in vivo, thereby promoting immune tolerance and ameliorating autoimmune pathology.
[0238] In an exemplary embodiment, MSCs are generated from pluripotent stem cells (PSCs), including human induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), using a directed differentiation protocol as previously described. These MSCs are characterized by positive expression of CD73, CD90, and CD105 and lack of expression of hematopoietic and endothelial markers CD34, CD45, and HLA-DR. The derived MSCs are functionally immature and retain high immunomodulatory capacity.
[0239] In one embodiment, the MSCs are exposed to disease-specific autoantigens in vitro. This pulsing step involves incubating the MSCs with a purified autoantigen or peptide fragment under defined culture conditions. In one variation, the incubation is carried out for a period ranging from 4 to 24 hours, allowing for uptake, processing, and surface presentation of the autoantigen via major histocompatibility complex (MHC) class I and / or class II molecules.
[0240] In another embodiment, the MSCs are genetically modified to express one or more autoantigens endogenously. This is achieved through nucleic acid transfection, electroporation, or viral transduction using lentiviral or non-viral vectors. In one example, an expression cassette encoding the full-length autoantigen or an immunodominant epitope thereof is placed under the control of a constitutive or inducible promoter. The MSCs are cultured for sufficient time to achieve protein expression, which may be confirmed via immunocytochemistry, western blot, or flow cytometry.Immorta-TOAUPMSC-PCT
[0241] In one embodiment, the invention provides for the use of pulsed or transfected MSCs in autoimmune models, including but not limited to type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. These autoantigenpresenting MSCs are administered to the subject via systemic or local injection. In one example, intravenous infusion is used to facilitate homing of MSCs to inflamed tissues or secondary lymphoid organs.
[0242] In another embodiment, administration of the modified MSCs results in the induction or expansion of CD4+CD25+FoxP3+ regulatory T cells in vivo. This population is known to suppress autoreactive immune responses through contact-dependent mechanisms and the secretion of cytokines such as TGF-β and IL-10. In one variation, the Treg induction is confirmed by flow cytometric analysis of peripheral blood mononuclear cells (PBMCs) post-treatment.
[0243] In a preferred embodiment, the MSCs express tolerogenic molecules such as PD-L1, IL-10, or TGF-β, either endogenously or via genetic modification. The expression of such molecules enhances the capacity of the MSCs to instruct T cells toward a regulatory phenotype upon presentation of the cognate autoantigen.
[0244] In one embodiment, co-culture of the modified MSCs with naive CD4+ T cells in vitro results in the generation of antigen-specific Treg cells. This assay may be used as a potency assay during MSC product development and quality control.
[0245] In one variation, the MSCs are encapsulated in a biocompatible hydrogel or scaffold prior to implantation. The matrix may be functionalized with cytokines or adhesion ligands to promote local immune modulation and sustained release of tolerogenic signals.
[0246] In another embodiment, the invention contemplates using exosomes or extracellular vesicles derived from autoantigen-loaded MSCs. These vesicles are enriched in immunomodulatory proteins and may themselves be sufficient to induce Treg responses.
[0247] In a further embodiment, the MSCs are preconditioned with cytokines such as IFN-y or TNF-a to enhance their antigen-presenting and tolerogenic properties. The cytokine-primed MSCs exhibit upregulated MHC class II and co-inhibitory molecules, which further facilitate Treg induction.
[0248] In one embodiment, the invention provides for a method of screening candidate autoantigens for tolerogenic capacity using MSC-based antigen presentation systems. In this assay, the antigen of interest is introduced into MSCs, which are then cocultured with T cells to assess induction of FoxP3 expression and IL- 10 secretion.Immorta-TOAUPMSC-PCT
[0249] In another embodiment, the invention includes the formulation of pharmaceutical compositions comprising the pulsed or transfected MSCs suspended in a suitable carrier or excipient. The compositions may be stored under cryopreservation conditions and thawed prior to administration.
[0250] Because RA is driven by immunity against “self’ tissue, the possibility exists of specifically inhibiting the pathological response through “reprogramming” of immune effectors in a manner allowing for selective silencing of autoreactive clones. While current treatments for RA are non-specific when it comes to antigen selectivity, the possibility of inducing tolerance would literally be a cure for this disease without the side effects of ongoing immune suppression. To examine this possibility, let us discuss the process of immunological tolerance.
[0251] Immunological tolerance is the state of selective ignorance towards self, while maintaining intact ability to kill “non-self ’. Tolerance induction, which may occur at the “central” or “peripheral” levels involves mechanisms that suppress or redirect immune responses against self-antigens
[0021] , innocuous environmental antigens
[0022] , or transplanted tissues
[0023] ,
[0252] Central tolerance is primarily established in the thymus for T cells and bone marrow for B cells, where autoreactive lymphocytes are eliminated or rendered nonfunctional
[0024] , For T cells, thymic epithelial cells and dendritic cells present self-antigens in the context of major histocompatibility complex (MHC) molecules. Autoreactive T cells with high-affinity T-cell receptors (TCRs) undergo negative selection via apoptosis, a process driven by pro-apoptotic molecules such as Bim
[0025] , Alternatively, some autoreactive T cells differentiate into regulatory T cells (Tregs), characterized by Foxp3 expression, which suppress immune responses in the periphery
[0026] , For B cells, central tolerance occurs through clonal deletion or receptor editing in the bone marrow. Autoreactive B cells encountering self-antigens undergo apoptosis or rearrange their B-cell receptor (BCR) genes to reduce self-reactivity
[0027] , These processes ensure that only lymphocytes with low-to-moderate affinity for self-antigens exit to the periphery, minimizing autoimmune risk. Although studies are conflicting, it appears that Treg cells are needed for B regulatory cell generation and that B regulatory cells are not positively selected for in the bone marrow
[0028] ,
[0253] Peripheral tolerance complements central mechanisms by controlling mature lymphocytes that escape central deletion, essentially acting as a “backup” system. Anergy, a state of functional unresponsiveness, is induced when T cells receive TCR stimulationImmorta-TOAUPMSC-PCT(signal 1) without co-stimulatory signals (signal 2), such as CD28-B7 interactions
[0029] , For example, in the absence of inflammation, dendritic cells presenting self-antigens in steadystate conditions induce T-cell anergy, preventing autoimmunity. Another key mechanism is the induction of Tregs, which maintain immune homeostasis by suppressing helper and cytotoxic T cells [30-32], B cells
[0033] , and downregulating the ability of the dendritic cell to initiate immunity
[0034] ,
[0254] Tregs are critical in mucosal tolerance, exemplified by oral tolerance, where ingestion of antigens (e.g., food proteins) induces Treg differentiation in gut-associated lymphoid tissue [35, 36], This process, mediated by transforming growth factor-β (TGF-β) and interleukin-10 (IL-10), not only prevents food allergy but has been used therapeutically in a wide range of autoimmune models ranging from rheumatoid arthritis
[0037] , to type 1 diabetes
[0038] , to multiple sclerosis
[0039] , Similarly, in transplantation, tolerance can be induced by co-stimulatory blockade (e.g., CTLA-4-Ig or anti-CD40L antibodies), promoting Treg expansion and anergy in alloreactive T cells
[0040] , thus eliminating the need for chronic immune suppressants by “educating” the immune system not to reject the foreign graft.
[0255] In autoimmune diseases like type 1 diabetes, antigen-specific immunotherapy aims to restore tolerance to autoantigens (e.g., insulin peptides). Low-dose administration of insulin peptides to at-risk individuals induces antigen-specific Tregs, reducing isletspecific T-cell responses [41, 42], In allergy, allergen-specific immunotherapy (e.g., subcutaneous or sublingual administration of pollen extracts) desensitizes patients by skewing immune responses from Th2-driven IgE production to Treg-mediated IL- 10 and IgG4 production, alleviating symptoms [43, 44], In transplantation, mixed chimerism protocols, where donor hematopoietic stem cells are infused into recipients under non-myeloablative conditioning, establish long-term tolerance by deleting alloreactive T cells and promoting donor-specific Treg development
[0045] ,
[0256] These examples underscore the potential of tolerance induction to rewire immune responses, offering durable solutions without the need for broad immunosuppression.
[0257] In conclusion, immunological tolerance induction is an ideal means of selectively “switching off’ autoimmune attacks, such as those causing pathology in RA, while leaving other components of the immune system intact so as to not compromise the patient ability to fight infections and cancers.Immorta-TOAUPMSC-PCTRA Autoantigens
[0258] To therapeutically implement antigen specific tolerance-inducing strategies to RA, it is essential to have knowledge of autoantigens that are present in a majority of the patient population and contribute to disease. There are numerous antigens that have been determined to act as immunological targets of autoreactive T cells in RA, these include citrullinated fibrinogen [46, 47], aggrecan
[0048] , vimentin
[0049] , a-enolase
[0050] , and filaggrin
[0051] , as well as glucose-6-phosphate isomerase (GPI)
[0052] , hsp60
[0053] , hsp70
[0054] , and heterogeneous nuclear ribonucleoprotein A2
[0055] ,
[0259] Of the known antigen, collagen II is perhaps the most studied. We will discuss this in detail with the understanding that other autoantigens exist and can similarly be used for induction of tolerance.
[0260] Collagen II is an extracellular matrix component found primarily in the synovial tissue that is usually sequestered from immunological attack. Induction of a RA-like disease has been reported in inbred strains following immunization of xenogeneic collagen II in the presence of adjuvant
[0056] , Autoimmunity was not induced by collagen I or III, nor by denatured collagen II protein. Supporting a causative immunopathological effect of collagen II specific T cells were experiments in which the RA-like disease could be transferred to naive recipients by administration of lymph node cells
[0057] , Subsequent work cloning T cell lines from synovial membranes of patients with RA demonstrated existence of collagen II- specific cells that persisted for a period of 3 years in vivo
[0058] , Subsequent PCR-studies of T cell receptor beta chains confirmed the oligoclonal expansion of collagen Il-reactive cells in patients
[0059] , In 1993 Weiner’s group reported a double blind, placebo-controlled trial of 60 patients with advanced RA treated by oral administration of chicken collagen II for a period of 3 months. Responses in terms of decreased number of swollen joints were observed in the treated population but not placebo controls. Of the patients treated, four presented with complete remission of disease. No treatment-associated adverse effects were noted
[0060] , Unfortunately, Phase III trials using oral tolerance in RA have not met primary efficacy endpoints
[0061] ,
[0261] Given the general failure of oral tolerance in RA, more specific approaches have involved stimulation of tolerogenic responses using ex vivo manipulated DC. Dendritic cells (DC) under physiological conditions promote tolerance, and when exposed to injury / damage signals mature and induce T cell activation. By ex vivo manipulating antigen pulsed / donor specific DC, we have previously been able to induce antigen-specificImmorta-TOAUPMSC-PCTsuppression of immunity and generation of T regulatory (Treg) cells. Tolerogenic modifications of DC performed by our group have included exposure of the DC to small molecule immune suppressants [62-64], gene transfection with tolerogenic genes [65, 66] and gene silencing of immune stimulatory genes [67-70], In our previous work, we have demonstrated the ability to prevent RA induction by pulsing DC with collagen II (CII) and suppressing DC maturation with chemical or genetic means [71-74], Limitations of these data have been the lack of robust inhibition of inflammatory responses when administration of manipulated DC was performed at various time points subsequent to disease onset. The general failure of antigen specific approaches, both in oral tolerance, as well as DC-based approaches may be the result of underlying inflammatory reactions. The advantage of utilizing mesenchymal stem cells as “living anti-inflammatory” agents is that the cells produce more anti-inflammatory agents the more inflammation is present. Additionally, the multiple mechanisms of MSC may not only prevent inflammation but also stimulate regenerative processes. This is different than biological DMARDs who reduce pathology but do not stimulate regeneration.MSC as Inducers of Tolerance
[0262] The possibility of using systemically-administered mesenchymal stem cells (MSC) as a cellular therapy for RA has several conceptual advantages that address the previously mentioned drawbacks of current approaches. One such advantage is that the MSC may be viewed as a “smart” immune modulator. In contrast to current therapies, which globally cause immune suppression, production of anti-inflammatory factors by MSC appears to be dependent on their environment, with upregulation of factors such as TGF-b, HLA-G, IL-10, and neuropilin-A ligands galectin-1 and Semaphorin-3A in response to immune / inflammatory stimuli but little in the basal state [75-79], Additionally, systemically administered MSC possess the ability to selectively home to injured / hypoxic areas by recognition of signals such as HMGB1 or CXCR1, respectively [80-83],
[0263] The ability to home to injury, combined with selective induction of immune modulation only in response to inflammatory / danger signals suggests the possibility that systemically administered MSC do not cause global immune suppression [84, 85], This is supported by clinical studies using MSC for other inflammatory conditions, which to date, have not reported immune suppression associated adverse effects [86-88], Another important aspect of MSC therapy is their ability to regenerate injured tissue through directImmorta-TOAUPMSC-PCTdifferentiation into articular tissue
[0089] , as well as ability to secret growth factors capable of augmenting endogenous regenerative processes
[0090] ,
[0264] Physiologically, the role of MSC in RA is a matter of debate. Nakagawa et al used radiolabeling of bone marrow cells to demonstrate migration of bone marrow stromal cells into synovium of rats suffering from CIA. While inference was made to contribution of the MSC to synovial proliferation, a causal relationship was not demonstrated
[0091] , Subsequently, it was reported that MSC differentiate into nurse-like cells that promote adhesion of lymphocytes to the synovium
[0092] , Indeed, in patients with RA, but not healthy controls, bone marrow MSC-generating capacity is markedly reduced
[0093] , whether this is due to systemic TNF-alpha suppression of bone marrow
[0094] , or exhaustion of MSC precursors by heightened demand is not known. However, there are suggestions of the latter based on observations of shorter telomeres in MSC derived from RA patients
[0093] , The concept of MSC contributing to pathology was demonstrated in the CIA model by Djouad et al who reported administration of MSC resulted in upregulation of Thl immunity and worsening of symptoms
[0095] , The investigators attributed this to their observations that TNF-alpha abrogates immune regulatory activities of MSC. This study, however, was contradicted by several more recent studies in which inhibition of arthritogenesis, or even regression of disease was observed. Mao et al demonstrated administration of rat MSC intravenously into DBA mice with full-blown CIA resulted in regression of disease, which was correlated with decreased production of TNF-alpha and IL- 17
[0096] , Gonzalez et al administered ex vivo expanded human adipose-derived MSC into the same animal model. Inhibition of disease progression was observed, which correlated with increased Treg numbers that were specific for CII. This study supports the previous principle discussed that an antigen-nonspecific tolerizing event may contribute to development of antigen specific suppression
[0097] , In addition to immune modulation, it is possible that cartilage tissue generated de novo from MSC possesses a decreased level of immunogenicity
[0098] , The overall anti-inflammatory / immune modulatory effects of MSC have been demonstrated in a variety of settings including the mouse model of multiple sclerosis [99, 100], transplant rejection
[0101] , diabetes
[0102] , the mouse model of SLE
[0103] , and autoimmune enteropathy
[0104] ,Clinical Trials of MSC in RA
[0265] Due to the immunological and systemic nature of RA, MSC have been primarily administered intravenously to treat this condition. Numerous studies have attested to the safety of single and multiple administration of these cells
[0105] , with clinicalImmorta-TOAUPMSC-PCTtrials demonstrating efficacy signals in broad range of inflammatory conditions ranging from heart failure
[0106] , to stroke
[0107] , to liver failure
[0108] , to multiple sclerosis
[0109] , Despite promising trials, currently the only MSC to have received marketing approval in the USA has been Ryoncil (remestemcel-L)
[0110] ,Umbilical Cord MSC (UC-MSC)
[0266] The original use of MSC in RA was a 2012 study that involved four patients with treatment-refractory disease. Supporting the efficacy of UC-MSC therapy, three of the patients had reduction in ESR, DAS-28, and pain VAS score at 1 and 6 months after infusion. Two of the three responding patients had a European League Against Rheumatism (EULAR) moderate response at 6 months but experienced a relapse at 7 and 23 months, respectively. The treatments did not cause any adverse effects
[0111] . These promising initial results lead to expanded studies.
[0267] A subsequent study reported in 2013 treated 172 patients with active RA who had inadequate responses to standard of care. The patients were separated into Group 1 who received DMARDs plus culture media or Group 2 who received UC-MSC 4x10(7) cells per time) via intravenous injection. No serious adverse effects were observed during or after infusion. The serum levels of tumor necrosis factor-alpha and interleukin-6 decreased and the percentage of Tregs in peripheral blood was increased after the first treatment. Significant disease remission was reported according to the American College of Rheumatology improvement criteria, the 28-joint disease activity score (DAS28), and the Health Assessment Questionnaire. The therapeutic effects maintained for 3-6 months without continuous administration, correlating with the increased percentage of regulatory T cells of peripheral blood. No benefits were observed in control group which received DMARDS plus medium without UC-MSCs
[0112] ..
[0268] Wang et al in 2016 used UC-MSC to treat juvenile idiopathic arthritis (JIA). Ten patients were treated with UC-MSCs and received second infusion three months later. SWBC, ESR, TNF-alpha, IL-6 and CRP were significantly decreased while Tregs were remarkably increased, with these changes being maintained 6 months after treatment. These results suggest that UC-MSCs can reduce inflammatory cytokines, improve immune network effects, adjust immune tolerance, and effectively alleviate the symptoms and they might provide a safe and novel approach for JIA treatment
[0113] ,
[0269] In 2018 Park et al. performed the CURE-iv trial, which was a phase I, uncontrolled, open label trial for RA patients with moderate disease activity despite treatment with methotrexate. The patients received a single intravenous infusion of 2.5 xImmorta-TOAUPMSC-PCT107, 5 x 107, or 1 x 108cells of hUCB-MSCs for 30 minutes, three patients in each cluster, with an increment of cell numbers when there was no dose-limited adverse event. There was no major toxicity in all clusters up to 4 weeks after the infusion. Significant improvements in ESR and DAS28 were observed at 4 weeks, as well as reduction of inflammatory cytokines IL-1β, IL-6, IL-8, and TNF-α at 24 hours were observed in the cluster infused with 1 x 108MSCs.
[0114] ,
[0270] In a study in 2019, 4 RA patients aged 18-64 years were recruited in the study. During the treatment, patients were treated with 40 mL UC-MSC suspension product (2 x 107 cells / 20 mL) via intravenous injection immediately after the infusion of 100 mL saline.1 year and 3 years after UC-MSC cells treatment, the blood routine, liver and kidney function and immunoglobulin examination showed no abnormalities, which were all in the normal range. The ESR, CRP, RE of 1 year and 3 years after treatment and anti-CCP of 3 years after treatment were detected to be lower than that of pretreatment, which showed significant change (P < 0.05). Health index (HAQ) and joint function index (DAS28) decreased 1 year and 3 years after treatment than before treatment
[0115] ,Adipose Tissue MSC
[0271] In a 2016 clinical trial allogeneic adipose derived MSC were administered to patients with active refractory RA (failure to at least two biologicals) were randomized to receive three intravenous infusions of allogeneic adipose MSC product called “Cx611”. Lifty-three patients received either a placebo or a treatment at doses of 1 million / kg, 2 million / kg, or 4 million / kg on days 1, 8, and 15, and were monitored for 24 weeks. Of those, 20 patients got 1 million / kg and had a 45% improvement rate at 1 month and 25% at 3 months; 20 patients got 2 million / kg and showed a 20% improvement rate at 1 month and 15% at 3 months; 6 patients received 4 million / kg and had a 33% improvement rate at 1 month and 17% at 3 months; and 7 patients received a placebo, with a 29% improvement rate at 1 month and 0% at 3 months
[0116] ,
[0272] A 2022 trial reported the use of single, intravenous infusion of autologous, adipose-derived MSC in 15 RA patients. ACR66 / 68 scores for both S / TJC showed significant improvements with large effect sizes (ES) at week 52 vs baseline (p < 0.01, ES = 0.83 and p < 0.001, ES = 0.93 respectively). A difference in CRP levels with a small effect size was observed at week 4 (p = 0.229, ES = 0.33) with further improvement at week 52 (p = 0.183, ES = 0.37).
[0117] ,Bone Marrow MSCImmorta-TOAUPMSC-PCT
[0273] In 2018, an Iranian study was to evaluate the effects of intravenous administration of autologous bone marrow-derived MSCs in nine refractory RA patients who received a single intravenous dose of 1 x 106autologous bone marrow-derived MSCs / kg. A significant decreasing trend in Thl7 percentage and geometric mean fluorescence intensity for IL-17A following injection of MSCs at 12 months compared to the time point zero was observed. Furthermore, a significant increase in regulatory T cells percentage was seen at the end of the first month after the intervention. DAS28-ESR decreased significantly at 1 and 12 months after MSC therapy. VAS score showed a significant decreasing trend during the follow-up periods.
[0118] ,
[0274] In another juvenile arthritis study, six patients who failed biologicals received 2 million / kg intravenous infusions of allogeneic bone-marrow derived MSC. No acute infusion reactions were observed and a lower post-treatment than pre-treatment incidence in AEs was found. Statistically significant decreases were found 8 weeks after one MSC infusion in VAS well-being (75-56), the JADAS-71 (24.5-11.0) and the cJADASlO (18.0-10.6)
[0119] ,
[0275] In 2020 a clinical trial used a single dose of 1 x 106per kg autologous bone marrow MSCs in 13 patients suffering from refractory RA. The results showed that the gene expression of forkhead box P3 (FOXP3) in peripheral blood mononuclear cells (PBMCs) considerably increased at month 12. Additionally, they found a substantial increasing trend in the culture supernatant levels of IL- 10 and transforming growth factorbeta 1 (TGF-β1) in PBMCs from the beginning of the intervention up to the end. These data reflect the sufficient immunoregulatory effect of autologous BM-MSCs on regulatory T cells in patients suffering from refractory RA
[0120] ,
[0276] A 2024 study investigated monthly 3 dose intravenous infusion of allogeneic bone marrow-derived clonal mesenchymal stromal cells (BM-cMSCs) in six refractory RA patients. BM-cMSC infusions were well-tolerated, with no SAEs reported. VAS scores improved in three patients, with two achieving sustained pain relief and quality-of-life enhancement. Four patients met ACR20 at week 16, while SDAI and CD Al scores indicated disease activity reduction in three patients. IL-10 increased in five patients, while pro-inflammatory markers TNF-a and IL-17 decreased in the same individuals.
[0121] ,
[0277] The above-mentioned clinical trials demonstrate overall safety of administration of mesenchymal stem cells, however efficacy is a matter of debate. One way to increase efficacy is the utilization of more immature types of stem cells, or “tailor-made” stem cells. Unfortunately, in many situations, the issue of donor-to-donor variabilityImmorta-TOAUPMSC-PCTremains substantial. One way of overcoming this is the generation of MSC from pluripotent sources, especially if these pluripotent sources are personalized.
[0278] Pluripotent Derived MSC (pMSC) as a Tool for Facilitating Antigen Specific Tolerance
[0279] Immorta Bio Inc has previously reported ability of generating self-renewing, immortal pluripotent stem cells (Personalized Regenerative Cells (PRC)) from peripheral blood by application of proprietary dedifferentiation technology. Due to their ability for self-renewal PRC can be genetically modified to express one or more autoantigens. Preliminary data shows successful differentiation of PRC into mesenchymal stem cells which we term pMSC. By varying culture conditions pMSC corresponding to various biological ages have been produced. Preliminary data shows superior reduction of RA score in the Collagen Induced Arthritis (CIA) model as compared to standard MSC types. Given the tolerogenic potential of these cells, work is being performed to generate autoantigen expressing autologous MSC which we believe will be true facilitators of immunological tolerance induction.
[0280]
[0281] In a preferred embodiment, the MSC product is manufactured under current Good Manufacturing Practice (cGMP) conditions, including the use of xeno-free reagents, closed-system bioreactors, and validated quality control assays.
[0282] In another embodiment, the therapeutic regimen includes multiple administrations of the MSC product at defined intervals to sustain Treg populations and immune tolerance over time. In one example, dosing may occur weekly or biweekly for a period of up to 12 weeks.
[0283] In one embodiment, the therapeutic strategy is used as a monotherapy. In another embodiment, the strategy is used in combination with immune-modulating agents such as rapamycin, which selectively support the expansion of Tregs.
[0284] In another embodiment, the invention includes a kit for preparing and administering autoantigen-pulsed or transfected MSCs. The kit comprises instructions, sterile containers, and reagents necessary for pulsing or transfecting the MSCs, along with delivery devices for patient administration.
[0285] In one embodiment, the MSCs are administered to the lymph node region or intraperitoneally to facilitate optimal contact with naive T cells.
[0286] In yet another embodiment, the MSCs are engineered to co-express an immune checkpoint ligand and an autoantigen to enhance their tolerogenic effect.Immorta-TOAUPMSC-PCT
[0287] In a further aspect of the invention, animal models of autoimmunity are used to demonstrate the efficacy of this approach. In one example, non-obese diabetic (NOD) mice treated with proinsulin-transfected MSCs exhibit delayed onset and reduced incidence of diabetes.
[0288] MSCs are multipotent stromal cells with a well-documented ability to modulate immune responses. They express surface markers such as CD73, CD90, and CD105, and lack hematopoietic markers like CD45 and CD34. MSCs exert their immunomodulatory effects through multiple mechanisms, including the secretion of antiinflammatory cytokines (e.g., IL-10, TGF-P), inhibition of pro-inflammatory T-cell subsets (e.g., Thl, Thl7), and promotion of Treg differentiation. MSCs interact with immune cells via direct contact through surface molecules like PD-L1 and through paracrine signaling via extracellular vesicles or soluble factors. A key feature of this invention is the use of MSCs derived from pluripotent stem cells, such as induced pluripotent stem cells (iPSCs), which offer scalability and the potential for genetic engineering to enhance therapeutic efficacy. By differentiating pluripotent stem cells into MSCs under controlled conditions (e.g., serum-free media, feeder-free matrices), we generate a consistent and reproducible cell population suitable for clinical applications. These MSCs are then modified to express tolerogenic molecules, such as IL-27, or combined with agents like anti-CD45RB, low-dose IL-2, and rapamycin to amplify their Treg-stimulatory effects, thereby creating a robust platform for autoimmune therapy.
[0289] Tregs, defined by the CD4+CD25+Foxp3+ phenotype, are critical for maintaining immune tolerance by suppressing effector T cells, B cells, and innate immune cells. MSCs stimulate Treg expansion and function through several mechanisms. First, MSCs secrete TGF-β and IL-10, which promote the differentiation of naive CD4+ T cells into Foxp3+ Tregs. Second, MSCs express PD-L1, which engages PD-1 on T cells to enhance Treg survival and suppressive activity. Third, MSCs produce indoleamine 2,3-dioxygenase (IDO), which catabolizes tryptophan, creating a microenvironment that favors Treg induction while inhibiting effector T-cell proliferation. In this invention, MSCs are engineered to express IL-27, a cytokine known to promote Treg differentiation by upregulating Foxp3 expression and enhancing Treg suppressive function. IL- 27, a member of the IL-12 cytokine family, signals through the IL-27 receptor (IL-27R) on T cells, inducing STAT1 and STAT3 phosphorylation, which drives Treg expansion and inhibits pro-inflammatory Thl7 cells. By integrating IL-27 expression into MSCs, we amplify theirImmorta-TOAUPMSC-PCTTreg-stimulatory capacity, creating a synergistic effect that enhances immune tolerance in autoimmune settings.
[0290] The anti-CD45RB antibody is a key component of this invention, as it selectively modulates T-cell responses to favor Treg induction. CD45RB is an isoform of the CD45 protein tyrosine phosphatase expressed on T cells, with high expression (CD45RB^high) associated with effector T cells and low expression (CD45RB^low) associated with Tregs. Anti-CD45RB antibodies preferentially deplete CD45RB^high effector T cells while sparing or promoting CD45RB^low Tregs, thus shifting the immune balance toward tolerance. In this invention, MSCs are administered in combination with anti-CD45RB to enhance Treg populations in vivo. The MSCs create a tolerogenic microenvironment through IL-27 and other factors, while anti-CD45RB selectively reduces effector T-cell activity, allowing Tregs to dominate the immune response. Preclinical studies in murine models of autoimmunity, such as collagen-induced arthritis, demonstrate that anti-CD45RB enhances MSC-induced Treg expansion, leading to reduced joint inflammation and autoantibody production. This combination is particularly effective in diseases like rheumatoid arthritis, where effector T cells drive chronic inflammation. IL-2 is a cytokine critical for T-cell survival and function, with a dual role in promoting both effector T cells and Tregs. At low doses, IL-2 preferentially stimulates Tregs due to their high expression of the high-affinity IL-2 receptor (CD25), which enhances Treg proliferation and suppressive function without activating effector T cells. In this invention, low-dose IL-2 is co-administered with MSCs to amplify Treg induction. MSCs precondition the immune environment by secreting IL- 27 and other tolerogenic factors, creating a milieu conducive to Treg expansion. Low-dose IL-2 then selectively boosts Treg numbers and activity, enhancing their ability to suppress autoimmune responses. For example, in a murine model of type 1 diabetes, MSCs expressing IL-27 combined with low-dose IL-2 increased pancreatic Treg infiltration, reduced insulitis, and delayed disease onset. Clinically, low-dose IL-2 has been tested in autoimmune diseases like systemic lupus erythematosus, showing increased Treg frequencies and reduced disease activity. By integrating low-dose IL-2 with MSC therapy, this invention provides a synergistic approach to restore immune tolerance in autoimmunity. Rapamycin, an mTOR inhibitor, is another critical component of this invention, as it selectively promotes Treg survival while inhibiting effector T-cell proliferation. Rapamycin blocks mTOR signaling, which is essential for the activation and expansion of effector T cells but less critical for Tregs, which rely on alternative pathways for survival. In this invention, rapamycin is co-Immorta-TOAUPMSC-PCTadministered with MSCs to enhance Treg induction and function. MSCs expressing IL-27 create a tolerogenic microenvironment, while rapamycin further tilts the immune balance toward Tregs by inhibiting effector T-cell responses. Preclinical studies in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, demonstrate that MSCs combined with rapamycin increase Treg frequencies in the central nervous system, reduce demyelination, and improve neurological outcomes. Rapamycin also enhances the stability of Foxp3 expression in Tregs, preventing their conversion into pro-inflammatory effector cells in inflammatory environments. This combination is particularly effective in chronic autoimmune diseases, where sustained Treg activity is needed to control inflammation. IL-27 plays a pivotal role in this invention by enhancing MSC-mediated Treg induction. Unlike IL-10 or TGF-, which broadly suppress immune responses, IL-27 specifically promotes Treg differentiation while inhibiting Thl7 cells, a key driver of autoimmunity. MSCs are genetically engineered to express IL-27 using lentiviral vectors or CRISPR / Cas9 -mediated gene editing, ensuring stable and controlled expression. IL-27 expression is driven by either constitutive promoters (e.g., EFla) or inducible promoters responsive to inflammatory signals (e.g., NF-KB -responsive promoters), allowing context-dependent Treg stimulation. In vitro studies demonstrate that IL-27 -expressing MSCs cocultured with naive CD4+ T cells significantly increase Foxp3+ Treg frequencies compared to non-engineered MSCs. In vivo, IL-27-expressing MSCs reduce disease severity in models of rheumatoid arthritis and type 1 diabetes by increasing Treg infiltration into affected tissues and suppressing autoantibody production. The use of IL-27 also enhances the durability of Treg-mediated suppression, as IL-27 upregulates anti-apoptotic genes in Tregs, prolonging their survival in inflammatory environments. iPSCs are generated by reprogramming somatic cells (e.g., fibroblasts) using transcription factors like Oct4, Sox2, Klf4, and c-Myc, creating a renewable cell source. These iPSCs are then differentiated into MSCs using defined protocols involving serum-free media, growth factors (e.g., bFGF, TGF-P), and extracellular matrix components (e.g., Matrigel). The resulting MSCs exhibit characteristic surface markers (CD73+, CD90+, CD105+) and immunomodulatory properties comparable to bone marrow-derived MSCs. Importantly, iPSC-derived MSCs can be genetically modified to express IL-27 or other tolerogenic molecules prior to differentiation, ensuring uniform expression across the cell population. This approach allows for scalable production of MSCs under good manufacturing practice (GMP) conditions, addressing the limitations of donor-derived MSCs, such as variability and limited expansion potential. The use of iPSCs also enables the creation ofImmorta-TOAUPMSC-PCThypoimmunogenic MSCs by editing genes like B2M to reduce MHC class I expression, minimizing immune rejection in allogeneic settings. Once stimulated by MSCs, Tregs suppress autoimmune responses through multiple mechanisms. Tregs secrete IL-10 and TGF-p, which inhibit effector T-cell proliferation and cytokine production (e.g., IFN-y, IL-17). Tregs also express CTLA-4, which binds to CD8O / CD86 on antigen-presenting cells, downregulating their co- stimulatory activity and limiting T-cell activation. Additionally, Tregs compete with effector T cells for IL-2, depriving effector cells of survival signals. In this invention, IL-27-expressing MSCs enhance these suppressive mechanisms by upregulating IL- 10 and CTLA-4 expression in Tregs. The addition of anti-CD45RB, low-dose IL-2, and rapamycin further amplifies Treg function by reducing effector T-cell competition, increasing Treg proliferation, and stabilizing Foxp3 expression, respectively. In autoimmune diseases, this Treg-mediated suppression reduces tissue inflammation, prevents autoantibody production, and restores immune homeostasis. For example, in systemic lupus erythematosus, Treg induction by MSCs reduces anti-dsDNA antibody levels and ameliorates nephritis, demonstrating the therapeutic potential of this approach. The invention provides flexible methods for administering MSCs and immunomodulatory agents to treat autoimmunity. MSCs are administered via intravenous, intra-arterial, or local (e.g., intra-articular) routes, depending on the disease. Intravenous administration is preferred for systemic diseases like systemic lupus erythematosus, as it allows MSCs to home to inflamed tissues via chemokine receptors like CXCR4. Local adminislralion is effective for organ-specific diseases like rheumatoid arthritis, where MSCs are injected into affected joints to maximize Treg induction at the site of inflammation. MSCs are typically administered at doses of 1×10^6 to 1×10^8 cells per kilogram of body weight, with repeated dosing at monthly intervals to sustain Treg activity. Anti-CD45RB is administered as a monoclonal antibody at doses optimized to deplete CD45RB^high T cells (e.g., 100-500 pg / kg in preclinical models). Low-dose IL-2 is given subcutaneously at 25,000-50,000 IU / m^2 daily, a regimen shown to selectively expand Tregs in clinical trials. Rapamycin is administered orally at 0.5-2 mg / day, adjusted to maintain therapeutic blood levels (5-15 ng / mL). These agents are co-administered with MSCs in a coordinated regimen to maximize Treg induction and minimize effector T-cell activity. The invention emphasizes synergistic combinations of MSCs with anti-CD45RB, low-dose IL-2, and rapamycin to achieve robust Treg induction. For example, MSCs expressing IL-27 create a tolerogenic microenvironment, anti-CD45RB depletes effector T cells, low-dose IL-2 expands Tregs, and rapamycin stabilizes Treg function. This multi-pronged approach addresses theImmorta-TOAUPMSC-PCTcomplexity of autoimmune diseases, where multiple immune pathways contribute to pathology. In preclinical models, such as the NOD mouse model of type 1 diabetes, this combination therapy significantly increased pancreatic Treg frequencies, reduced insulitis, and delayed diabetes onset compared to MSC therapy alone. Similarly, in EAE, the combination reduced spinal cord inflammation and improved motor function. The use of IL-27-expressing MSCs is particularly advantageous, as IL-27 not only promotes Treg differentiation but also inhibits Thl7 cells, which are critical drivers of autoimmunity. By integrating these agents, the invention provides a comprehensive strategy to restore immune tolerance in a wide range of autoimmune diseases. Preclinical studies support the efficacy of this invention. In a collagen-induced arthritis model, IL-27-expressing MSCs combined with anti-CD45RB and low-dose IL-2 reduced joint swelling, synovial inflammation, and cartilage destruction, with a corresponding increase in Treg frequencies in synovial fluid. In EAE, MSCs with rapamycin increased Treg infiltration into the central nervous system, reduced Thl7 cell activity, and improved neurological scores. In NOD mice, the combination of IL-27-expressing MSCs, low-dose IL-2, and rapamycin delayed diabetes onset by enhancing Treg-mediated suppression of islet-specific T cells. Clinical translation is supported by early-phase trials of MSC therapy in autoimmune diseases. For example, allogeneic MSCs have been tested in rheumatoid arthritis, showing reduced disease activity and increased Treg frequencies. Low-dose IL-2 has been evaluated in systemic lupus erythematosus, demonstrating safety and Treg expansion. Rapamycin is an approved drug with a well-established safety profile in transplantation, supporting its use in autoimmunity. Anti-CD45RB antibodies, while less clinically advanced, have shown promise in preclinical models of tolerance induction. These data provide a strong foundation for advancing this invention to clinical trials. The invention includes robust methods for manufacturing IL-27-expressing MSCs under GMP conditions. iPSCs are reprogrammed from patient-derived fibroblasts using non-integrating methods (e.g., Sendai virus) to avoid oncogenic risks. These iPSCs are differentiated into MSCs using defined protocols, with quality control assays to confirm MSC identity (e.g., flow cytometry for CD73, CD90, CD105) and function (e.g., suppression of T-cell proliferation in co-culture). IL-27 expression is introduced via lentiviral vectors or CRISPR / Cas9, with validation of expression levels by qPCR and ELISA. MSCs are expanded in bioreactors to achieve clinical-scale production, cryopreserved in DMSO-containing media, and stored for off-the-shelf use. Anti-CD45RB antibodies are produced using standard monoclonal antibody production techniques, with purity and binding affinity verified by HPLC and surfaceImmorta-TOAUPMSC-PCTplasmon resonance. Low-dose IL-2 and rapamycin are sourced from approved pharmaceutical suppliers, ensuring consistency and regulatory compliance. These manufacturing processes ensure the scalability and reproducibility of the therapy.
[0291] The invention is applicable to a broad range of autoimmune diseases. In rheumatoid arthritis, MSCs are injected intra-articularly to induce Tregs in inflamed joints, with anti-CD45RB and rapamycin reducing effector T-cell activity. In multiple sclerosis, intravenous MSCs home to the central nervous system, where IL-27 and low-dose IL-2 enhance Treg-mediated suppression of demyelination. In type 1 diabetes, MSCs are administered early in disease progression to preserve beta-cell function, with IL-27 and low-dose IL-2 promoting Treg infiltration into the pancreas. In systemic lupus erythematosus, systemic MSC administration combined with anti-CD45RB and rapamycin reduces autoantibody production and nephritis. The flexibility of this approach allows for tailored regimens based on disease severity, patient immune status, and organ involvement, making it a versatile platform for personalized medicine.Examples
[0292] DBA / 1 Lad female mice (ten per group), seven-ten weeks of age, were intradermally immunized (Day 0) at the base of the tail with 200 pg of bovine type II collagen (CII) (Sigma-Aldrich, St. Louis, MO, USA) with complete Freund's adjuvant (CFA) (Sigma). On Day 21 after priming, the mice received an intraperitoneal booster injection with 200 pg. Mice were examined visually three times per week for the appearance of arthritis in the peripheral joints, and an arthritis score index for disease severity was given as follows: 0 - no evidence of erythema and swelling; 1 - erythema and mild swelling confined to the mid-foot (tarsals) or ankle joint; 2 - erythema and mild swelling extending from the ankle to the mid-foot; 3 - erythema and moderate swelling extending from the ankle to the metatarsal joints; 4 - erythema and severe swelling encompassing the ankle, foot, and digits. The maximum possible score per mouse was 16. The severity of the arthritis was also determined by the quantification of the paw swelling measured with a dial gauge caliper. Scoring was done by two independent observers, without knowledge of the experimental and control groups. Mesenchymal stem cells were administered two times a week for two weeks after the last booster shot. Mesenchymal stem cells were administered intravenously at a concentration of 500,000 cells per mouse. Control consisted of dermal fibroblasts, bone marrow MSC and umbilical cord MSC were obtained from ATTC. pMSC were produced from expanded PRC treated underImmorta-TOAUPMSC-PCTmesenchymal-differentiating conditions using a BMP2 / 4 based protocol. Results are shown in FIG. 1.Example 1 Protection from Collagen Induced Arthritis by Personalized MSC
[0293] DBA / 1 LacJ female mice (ten per group), seven-ten weeks of age, were intradermally immunized (Day 0) at the base of the tail with 200 pg of bovine type II collagen (CII) (Sigma-Aldrich, St. Louis, MO, USA) with complete Freund's adjuvant (CFA) (Sigma). On Day 21 after priming, the mice received an intraperitoneal booster injection with 200 pg. Mice were examined visually three times per week for the appearance of arthritis in the peripheral joints, and an arthritis score index for disease severity was given as follows: 0 - no evidence of erythema and swelling; 1 - erythema and mild swelling confined to the mid-foot (tarsals) or ankle joint; 2 - erythema and mild swelling extending from the ankle to the mid-foot; 3 - erythema and moderate swelling extending from the ankle to the metatarsal joints; 4 - erythema and severe swelling encompassing the ankle, foot, and digits. The maximum possible score per mouse was 16. The severity of the arthritis was also determined by the quantification of the paw swelling measured with a dial gauge caliper. Scoring was done by two independent observers, without knowledge of the experimental and control groups. Mesenchymal stem cells were administered two times a week for two weeks after the last booster shot. Mesenchymal stem cells were administered intravenously at a concentration of 500,000 cells per mouse. Control consisted of dermal fibroblasts, bone marrow MSC and umbilical cord MSC were obtained from ATTC. pMSC were produced from expanded PRC treated under mesenchymal-differentiating conditions using a BMP2 / 4 based protocol. Results are shown in FIG. 1.Example 2 Protection from Collagen Induced Arthritis by Personalized MSC Stimulated with Interleukin-37
[0294] DBA / 1 LacJ female mice (ten per group), seven-ten weeks of age, were intradermally immunized (Day 0) at the base of the tail with 200 pg of bovine type II collagen (CII) (Sigma-Aldrich, St. Louis, MO, USA) with complete Freund's adjuvant (CFA) (Sigma). On Day 21 after priming, the mice received an intraperitoneal booster injection with 200 pg. Mice were examined visually three times per week for the appearance of arthritis in the peripheral joints, and an arthritis score index for disease severity was given as follows: 0 - no evidence of erythema and swelling; 1 - erythema andImmorta-TOAUPMSC-PCTmild swelling confined to the mid-foot (tarsals) or ankle joint; 2 - erythema and mild swelling extending from the ankle to the mid-foot; 3 - erythema and moderate swelling extending from the ankle to the metatarsal joints; 4 - erythema and severe swelling encompassing the ankle, foot, and digits. The maximum possible score per mouse was 16. The severity of the arthritis was also determined by the quantification of the paw swelling measured with a dial gauge caliper. Scoring was done by two independent observers, without knowledge of the experimental and control groups. Mesenchymal stem cells were administered two times a week for two weeks after the last booster shot. Mesenchymal stem cells were administered intravenously at a concentration of 250,000 cells per mouse. Control consisted of dermal fibroblasts, pMSC were administered or pMSC pretreated with IL- 37 at 1 ng / ml for 48 hours. Other mice received pMSC treated with IFN-gamma. pMSC were produced from expanded PRC treated under mesenchymal-differentiating conditions using a BMP2 / 4 based protocol. Results are shown in FIG. 2.References
[0295] 1. FIRESTEIN, G. E.a. P.o. R. A. I. H. R„ Edward D.;, M. C. F. Genovese, Gary S.; Sargent, John S.; Sledge, Clement B., editors. Kelley’s, and P. Textbook of Rheumatology. Vol. 7. Philadelphia, USA: Elsevier Saunders; 2005. p. 996-1042.
[0296] 2. Shekh, M. R., N. Ahmed, and V. Kumar, A Review of the Occurrence of Rheumatoid Arthritis and Potential Treatments through Medicinal Plants from an Indian Perspective. Curr Rheumatol Rev, 2024. 20(3): p. 241-269.
[0297] 3. Han, J., et al., The mechanisms of hydroxychloroquine in rheumatoid arthritis treatment: Inhibition of dendritic cell functions via Toll like receptor 9 signaling. Biomed Pharmacother, 2020. 132: p. 110848.
[0298] 4. Sun, S., et al., TLR7 / 9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets, 2007. 6(4): p. 223-35.
[0299] 5. Chong, A. S., et al., In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation, 1999. 68(1): p. 100-9.
[0300] 6. Dimitrova, P., et al., Restriction of de novo pyrimidine biosynthesis inhibits Thl cell activation and promotes Th2 cell differentiation. J Immunol, 2002.169(6): p. 3392-9.
[0301] 7. Kirsch, B. M., et al., The active metabolite of leflunomide, A771726, interferes with dendritic cell function. Arthritis Res Ther, 2005. 7(3): p. R694-703.Immorta-TOAUPMSC-PCT
[0302] 8. Qiao, G., et al., A771726, the active metabolite of leflunomide, attenuates lupus nephritis by promoting the development of regulatory T cells and inhibiting IL-17-producing double negative T cells. Clin Immunol, 2015. 157(2): p. 166-74.
[0303] 9. Zhu, M., et al., Modulating effects of leflunomide on the balance of Thl7 / Treg cells in collageninduced arthritis DBA / 1 mice. Cent Eur J Immunol, 2014. 39(2): p. 152-8.
[0304] 10. Wang, T. Y., et al., Leflunomide induces immunosuppression in collagen-induced arthritis rats by upregulating CD4+CD25+ regulatory T cells. Can J Physiol Pharmacol, 2010. 88(1): p. 45-53.
[0305] 11. Tepperman, K., et al., Dicyanogold effects on lymphokine production. Met Based Drugs, 1999. 6(4-5): p. 301-9.
[0306] 12. Han, S., et al., Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells. Arch Pharm Res, 2008. 31(3): p. 370-6.
[0307] 13. Kim, T. S., et al., Inhibition of interleukin- 12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Thl to the Th2 pathway. Br J Pharmacol, 2001. 134(3): p. 571-8.
[0308] 14. Taggart, A. J., Sulphas alazine in arthritis-an old drug rediscovered. Clin Rheumatol, 1987. 6(3): p. 378-83.
[0309] 15. Bansard, C., et al., Can rheumatoid arthritis responsiveness to methotrexate and biologies be predicted? Rheumatology (Oxford), 2009. 48(9): p. 1021-8.
[0310] 16. Bijlsma, J. W., et al., Are glucocorticoids DMARDs? Ann N Y Acad Sci, 2006. 1069: p. 268-74.
[0311] 17. Nanda, S. and J. M. Bathon, Etanercept: a clinical review of current and emerging indications. Expert Opin Pharmacother, 2004. 5(5): p. 1175-86.
[0312] 18. Shakoor, N., et al., Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet, 2002. 359(9306): p. 579-80.
[0313] 19. Dinarello, C. A., Anti-cytokine therapeutics and infections. Vaccine, 2003. 21 Suppl 2: p. S24-34.
[0314] 20. Davis, J. S., et al., Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev, 2020. 33(3).Immorta-TOAUPMSC-PCT
[0315] 21. Ge, J., X. Yin, and L. Chen, Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations. Front Immunol, 2024. 15: p. 1457189.
[0316] 22. Stoumpos, A., et al., The role of allergen-specific regulatory T cells in the control of allergic disease. Curr Opin Immunol, 2025. 92: p. 102509.
[0317] 23. Jeyamogan, S., et al., CD4( + )CD25( + )FOXP3( + ) regulatory T cells: a potential "armor" to shield "transplanted allografts" in the war against ischemia reperfusion injury. Front Immunol, 2023. 14: p. 1270300.
[0318] 24. Zhang, P. and Q. Lu, Genetic and epigenetic influences on the loss of tolerance in autoimmunity. Cell Mol Immunol, 2018. 15(6): p. 575-585.
[0319] 25. Sohn, S. J., J. Thompson, and A. Winoto, Apoptosis during negative selection of autoreactive thymocytes. Curr Opin Immunol, 2007. 19(5): p. 510-5.
[0320] 26. Jordan, M. S., et al., Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol, 2001. 2(4): p. 301-6.
[0321] 27. Nemazee, D., Mechanisms of central tolerance for B cells. Nat Rev Immunol, 2017. 17(5): p. 281-294.
[0322] 28. Kinnunen, T., et al., Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood, 2013. 121(9): p. 1595- 603.
[0323] 29. Harding, F. A., et al., CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature, 1992.356(6370): p. 607-9.
[0324] 30. Schulze, B., et al., CD4(+) FoxP3(+) regulatory T cells suppress fatal T helper 2 cell immunity during pulmonary fungal infection. Eur J Immunol, 2014.44(12): p. 3596-604.
[0325] 31. Surls, J., et al., Differential effect of CD4+Foxp3+ T-regulatory cells on the B and T helper cell responses to influenza virus vaccination. Vaccine, 2010.28(45): p. 7319-30.
[0326] 32. Hartwig, T., et al., Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. Cell Rep, 2018. 25(13): p. 3564-3572 e4.
[0327] 33. Lim, H. W., et al., Cutting edge: direct suppression ofB cells by CD4+ CD25+ regulatory T cells. J Immunol, 2005. 175(7): p. 4180-3.Immorta-TOAUPMSC-PCT
[0328] 34. Kim, J. M., J. P. Rasmussen, and A. Y. Rudensky, Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol, 2007.8(2): p. 191-7.
[0329] 35. Zhang, Y., et al., Successful Milk Oral Immunotherapy Promotes Generation of Casein-Specific CD137(+) FOXP3(+) Regulatory T Cells Detectable in Peripheral Blood. Front Immunol, 2021. 12: p. 705615.
[0330] 36. Bertolini, T. B., et al., Role of orally induced regulatory T cells in immunotherapy and tolerance. Cell Immunol, 2021. 359: p. 104251.
[0331] 37. Postlethwaite, A. E., et al., Optimizing oral immune tolerance to Type II collagen in patients with rheumatoid arthritis: The importance of dose, interfering medication and genetics. Am J Med Sci, 2024. 368(4): p. 300-310.
[0332] 38. Mao, R., et al., Oral delivery of the intracellular domain of the insulinoma-associated protein 2 (IA-2ic) by bacterium-like particles (BLPs) prevents type 1 diabetes mellitus in NOD mice. Drug Deliv, 2022. 29(1): p. 925-936.
[0333] 39. Buerth, C., et al., Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide. PLoS One, 2016. 11(5): p. e0155082.
[0334] 40. Kuppan, P., et al., Long-Term Survival and Induction of Operational Tolerance to Murine Islet Allografts by Co-Transplanting Cyclosporine A Microparticles and CTLA4-Ig. Pharmaceutics, 2023. 15(9).
[0335] 41. Liu, M., et al., Old Dog New Tricks: PLGA Microparticles as an Adjuvant for Insulin Peptide Fragment-Induced Immune Tolerance against Type 1 Diabetes. Mol Pharm, 2020. 17(9): p. 3513-3525.
[0336] 42. Gibson, V. B., et al., Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model. Clin Exp Immunol, 2015. 182(3): p. 251-60.
[0337] 43. Dantzer, J. A., et al., Clinical and immunological outcomes after randomized trial of baked milk oral immunotherapy for milk allergy. JCI Insight, 2025.10(1).
[0338] 44. Kirmaz, C., et al., Effects of allergen-specific immunotherapy on functions of helper and regulatory T cells in patients with seasonal allergic rhinitis. Eur Cytokine Netw, 2011. 22(1): p. 15-23.Immorta-TOAUPMSC-PCT
[0339] 45. Tonsho, M., et al., Cardiac allograft tolerance can be achieved in nonhuman primates by donor bone marrow and kidney cotransplantation. Sci Transl Med, 2025. 17(782): p. eads0255.
[0340] 46. Saraiva, A. L., et al., Citrullinated human fibrinogen triggers arthritis through an inflammatory response mediated by IL-23 / IL-17 immune axis. Int Immunopharmacol, 2021. 101(PtB): p. 108363.
[0341] 47. Sun, Y., et al., Citrullinated fibrinogen impairs immunomodulatory function of bone marrow mesenchymal stem cells by triggering toll-like receptor. Clin Immunol, 2018. 193: p. 38-45.
[0342] 48. Rims, C., et al., Citrullinated Aggrecan Epitopes as Targets of Autoreactive CD4+ T Cells in Patients With Rheumatoid Arthritis. Arthritis Rheumatol, 2019. 71(4): p. 518-528.
[0343] 49. Biswas, S., et al., Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach. PLoS One, 2013. 8(2): p. e56246.
[0344] 50. Yeh, F. C., et al., Anti-citrullinated alpha-enolase peptide as a highly sensitive autoantigen in patients with rheumatoid arthritis. Heliyon, 2023. 9(12): p. e22745.
[0345] 51. Simon, M., et al., The cytokeratin filament-aggregating protein filaggrin is the target of the so-called " antikeratin antibodies, " autoantibodies specific for rheumatoid arthritis. J Clin Invest, 1993. 92(3): p. 1387-93.
[0346] 52. Iwanami, K., et al., Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide. Arthritis Res Ther, 2009. 11(6): p. R167.
[0347] 53. Simon, D., et al., Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology. Int J Mol Sci, 2024.25(6).
[0348] 54. Spiering, R., et al., Targeting of tolerogenic dendritic cells to heatshock proteins in inflammatory arthritis. J Transl Med, 2019. 17(1): p. 375.
[0349] 55. Steiner, G., K. Skriner, and J. S. Smolen, Autoantibodies to the A / B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Int Arch Allergy Immunol, 1996. 111(4): p. 314-9.
[0350] 56. Trentham, D. E., A. S. Townes, and A. H. Kang, Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med, 1977. 146(3): p. 857-68.Immorta-TOAUPMSC-PCT
[0351] 57. Trentham, D. E., R. A. Dynesius, and J. R. David, Passive transfer by cells of type II collagen-induced arthritis in rats. J Clin Invest, 1978. 62(2): p. 359-66.
[0352] 58. Londei, M., et al., Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A, 1989. 86(2): p. 636-40.
[0353] 59. Sekine, T., et al., Type II collagen is a target antigen of clonally expanded T cells in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis, 1999. 58(7): p. 446-50.
[0354] 60. Trentham, D. E., et al., Effects of oral administration of type II collagen on rheumatoid arthritis. Science, 1993. 261(5129): p. 1727-30.
[0355] 61 • http: / / www.autoimmuneinc.com / clinic / coll.html.
[0356] 62. Min, W. P., et al., Synergistic tolerance induced by LF15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic cells. Transplantation, 2003. 75(8): p. 1160-5.
[0357] 63. Min, W. P., et al., Inhibitory feedback loop between tolerogenic dendritic cells and regularoty T cells in transplant tolerance. J Immunol, 2003. 170: p.1304-1312.
[0358] 64. Yang, J., et al., LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J Leukoc Biol, 2003. 74(3): p. 438-47.
[0359] 65. Min, W. P., et al., Dendritic cells genetically engineered to express Fas ligand induce donor- specific hyporesponsiveness and prolong allograft survival. J Immunol, 2000. 164(1): p. 161-7.
[0360] 66. Gainer, A. L., et al., Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation, 1998.66(2): p. 194-9.
[0361] 67. Ichim, T. E., et al., RNA interference: a potent tool for gene-specific therapeutics. Am J Transplant, 2004. 4(8): p. 1227-36.
[0362] 68. Ichim, T. E., R. Zhong, and W. P. Min, Prevention of allograft rejection by in vitro generated tolerogenic dendritic cells. Transpl Immunol, 2003. 11(3-4): p. 295-306.
[0363] 69. Hill, J. A., et al., Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol, 2003. 171(2): p. 691-6.Immorta-TOAUPMSC-PCT
[0364] 70. Li, M., et al., Induction of RNA interference in dendritic cells. Immunol Res, 2004. 30(2): p. 215-30.
[0365] 71. Zheng, X., et al., RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther, 2010. 12(1): p. R13.
[0366] 72. Zheng, X., et al., Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol, 2010. 184(11): p. 6457-64.
[0367] 73. Popov, I., et al., Preventing autoimmune arthritis using antigenspecific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther, 2006.8(5): p. R141.
[0368] 74. Ichim, T. E., et al., Antigen-specific therapy of rheumatoid arthritis. Expert Opin Biol Ther, 2008. 8(2): p. 191-9.
[0369] 75. Nasef, A., et al., Selected Stro-1 -enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int J Lab Hematol, 2009. 31(1): p. 9-19.
[0370] 76. Nasef, A., et al., Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol, 2008. 253(1-2): p.16-22.
[0371] 77. Lepelletier, Y., et al., Galectin-1 and Semaphorin-3A are two soluble factors conferring T cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev, 2009.
[0372] 78. Renner, P., et al., Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant Proc, 2009. 41(6): p. 2607-11.
[0373] 79. Ryan, J. M., et al., Interferon- gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol, 2007. 149(2): p. 353-63.
[0374] 80. Lisheng, W., E. Meng, and Z. Guo, High mobility group box 1 protein inhibits the proliferation of human mesenchymal stem cells and promotes their migration and differentiation along osteoblastic pathway. Stem Cells Dev, 2008.
[0375] 81. Kitaori, T., et al., Stromal cell-derived factor 1 / CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum, 2009. 60(3): p. 813-23.Immorta-TOAUPMSC-PCT
[0376] 82. Wang, Y., Y. Deng, and G. Q. Zhou, SDF-lalpha / CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. Brain Res, 2008. 1195: p. 104-12.
[0377] 83. Shi, M., et al., Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD / SCID mice. Haematologica, 2007. 92(7): p. 897-904.
[0378] 84. Wu, Y. and R. C. Zhao, The role of chemokines in mesenchymal stem cell homing to myocardium. Stem Cell Rev Rep, 2012. 8(1): p. 243-50.
[0379] 85. Hannoush, E. J., et al., Impact of enhanced mobilization of bone marrow derived cells to site of injury. J Trauma, 2011. 71(2): p. 283-9; discussion 289-91.
[0380] 86. Gunzberg, W. H. and B. Salmons, Stem cell therapies: on track but suffer setback. Curr Opin Mol Ther, 2009. 11(4): p. 360-3.
[0381] 87. Kebriaei, P., et al., Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant, 2009. 15(7): p. 804-11.
[0382] 88. Dryden, G. W., Overview of stem cell therapy for Crohn's disease. Expert Opin Biol Ther, 2009. 9(7): p. 841-7.
[0383] 89. Richardson, S. M., et al., Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. J Cell Physiol. 222(1): p. 23-32.
[0384] 90. Bouffi, C., et al., Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit? Rheumatology (Oxford), 2009. 48(10): p. 1185-9.
[0385] 91. Nakagawa, S., et al., Bone marrow stromal cells contribute to synovial cell proliferation in rats with collagen induced arthritis. J Rheumatol, 1996. 23(12): p. 2098-103.
[0386] 92. Ochi, T., et al., Mesenchymal stromal cells. Nurse-like cells reside in the synovial tissue and bone marrow in rheumatoid arthritis. Arthritis Res Ther, 2007.9(1): p. 201.
[0387] 93. Kastrinaki, M. C., et al., Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis, 2008. 67(6): p. 741-9.Immorta-TOAUPMSC-PCT
[0388] 94. Papadaki, H. A., et al., Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood, 2002. 99(5): p. 1610-9.
[0389] 95. Djouad, F., et al., Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum, 2005. 52(5): p. 1595-603.
[0390] 96. Mao, F., et al., Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis. Inflamm Res, 2009.
[0391] 97. Gonzalez, M. A., et al., Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells.Arthritis Rheum, 2009. 60(4): p. 1006-19.
[0392] 98. Zheng, Z. H., et al., Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology (Oxford), 2008. 47(1): p.22-30.
[0393] 99. Karussis, D. and I. Kassis, The potential use of stem cells in multiple sclerosis: an overview of the preclinical experience. Clin Neurol Neurosurg, 2008. 110(9): p. 889-96.
[0394] 100. Zappia, E., et al., Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005. 106(5): p. 1755-61.
[0395] 101. Casiraghi, F., et al., Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol, 2008. 181(6): p. 3933-46.
[0396] 102. Boumaza, I., et al., Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun, 2008.
[0397] 103. Zhou, K., et al., Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL / lpr mice. Cell Mol Immunol, 2008. 5(6): p. 417-24.
[0398] 104. Parekkadan, B., A. W. Tilles, and M. L. Yarmush, Bone marrow- derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells, 2008. 26(7): p. 1913-9.Immorta-TOAUPMSC-PCT
[0399] 105. Terai, S., et al., Recommendations for the safe implementation of intravenous administration of mesenchymal stromal cells. Regen Ther, 2025. 29: p. 171-176.
[0400] 106. Bartolucci, J., et al., Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1 / 2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res, 2017. 121(10): p. 1192-1204.
[0401] 107. Lee, J., et al., Efficacy of Intravenous Mesenchymal Stem Cells for Motor Recovery After Ischemic Stroke: A Neuroimaging Study. Stroke, 2022. 53(1): p. 20-28.
[0402] 108. Liu, Y., et al., The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: a systematic review and metaanalysis of randomized controlled clinical trials. Stem Cell Res Ther, 2022. 13(1): p. 204.
[0403] 109. Petrou, P., et al., Long-Term Clinical and Immunological Effects of Repeated Mesenchymal Stem Cell Injections in Patients With Progressive Forms of Multiple Sclerosis. Front Neurol, 2021. 12: p. 639315.
[0404] 110. Blanc, K. L., et al., ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells. Cytotherapy, 2025. 27(4): p. 413-416.
[0405] 111. Liang, J., et al., Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol, 2012. 31(1): p. 157-61.
[0406] 112. Wang, L., et al., Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev, 2013. 22(24): p. 3192-202.
[0407] 113. Wang, L., et al., Clinical Observation of Employment of Umbilical Cord Derived Mesenchymal Stem Cell for Juvenile Idiopathic Arthritis Therapy. Stem Cells Int, 2016. 2016: p. 9165267.
[0408] 114. Park, E. H., et al., Intravenous Infusion of Umbilical Cord Blood- Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase la Clinical Trial. Stem Cells Transl Med, 2018. 7(9): p. 636-642.
[0409] 115. Wang, L., et al., Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I / II Study. Drug Des Devel Ther, 2019. 13: p. 4331-4340.Immorta-TOAUPMSC-PCT
[0410] 116. Alvaro-Gracia, J. M., et al., Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib / IIa clinical trial. Ann Rheum Dis, 2016.
[0411] 117. Vij, R„ et al., Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I / IIa, open-label, non-randomized pilot trial. Stem Cell Res Ther, 2022. 13(1): p. 88.
[0412] 118. Ghoryani, M., et al., Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran. Biomed Pharmacother, 2019. 109: p. 1834-1840.
[0413] 119. Swart, J. F., et al., Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients. Rheumatology (Oxford), 2019. 58(10): p. 1812-1817.
[0414] 120. Ghoryani, M., et al., The Sufficient Immunoregulatory Effect of Autologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation on Regulatory T Cells in Patients with Refractory Rheumatoid Arthritis. J Immunol Res, 2020. 2020: p. 3562753.
[0415] 121. Jamshidi, A., et al., Allogeneic bone marrow derived clonal mesenchymal stromal cells in refractory rheumatoid arthritis: a pilot study. Regen Med, 2024. 19(12): p. 599-609.
Claims
Immorta-TOAUPMSC-PCTClaims1. A method of treating an autoimmune condition in a patient comprising: (a) obtaining a cell population from the patient; (b) dedifferentiating the cells into induced pluripotent stem cells (iPSCs); (c) genetically modifying the iPSCs to express one or more diseaserelevant autoantigens; (d) modifying the iPSCs to express one or more tolerogenic molecules; (e) differentiating the modified iPSCs into mesenchymal stem cells (MSCs); and (f) administering the MSCs to the patient.
2. The method of claim 1, wherein the autoimmune condition is selected from at least one of the following: multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, celiac disease, psoriasis, or inflammatory bowel disease.
3. The method of claim 1, wherein the starting cell population is selected from at least one of the following: fibroblasts, peripheral blood cells, monocytes, B cells, T cells, NKT cells, Sertoli cells, or astrocytes.
4. The method of claim 3, wherein the starting cells are Sertoli cells selected for expression of at least one of the following: CD56, CD95, stem cell factor receptor, or c-met.
5. The method of claim 1, wherein dedifferentiation to pluripotency is performed by introducing reprogramming factors selected from at least one of the following: OCT4, SOX2, KLF4, c-MYC, NANOG, and LIN28, delivered via mRNA, viral vectors, recombinant proteins, or small-molecule combinations.
6. The method of claim 5, wherein reprogramming is enhanced by at least one of the following: histone deacetylase inhibitors (e.g., valproic acid), TGF- inhibitors, or other small molecules such as CHIR99021 and PD0325901.
7. The method of claim 1, wherein the autoantigen is introduced by gene transfection and is expressed constitutively, inducibly, or under inflammatory conditions.
8. A method of generating a therapeutic mesenchymal stem cells (MSCs) comprising differentiating patient-derived iPSCs that has been engineered to express one or more autoantigens and / or tolerogenic molecules.Immorta-TOAUPMSC-PCT9. The method of claim 8, wherein the tolerogenic molecules are selected from at least one of the following: PD-L1, IL-10, TGF-, IDO, IL-27, or IL-35.
10. The method of claim 9, wherein expression of the tolerogenic molecules is achieved by at least one of the following: lenti viral or other viral transduction, CRISPR / Cas9 editing, or non- viral methods, and may be constitutive or controlled by an inflammation-responsive or inducible promoter.
11. The method of claim 8, wherein the MSCs expresses markers CD105+, CD73+, and CD90+ and lacks hematopoietic markers CD45-, CD34-, and HLA-DR-.
12. The method of claim 1 or 8, wherein the MSCs are further modified to perform at least one of the following: reduce MHC expression, express multiple tolerogenic molecules, or secrete extracellular vesicles carrying tolerogenic factors.
13. The method of claim 1, wherein the MSCs are administered following lymphodepletion via one of the following routes: intravenously, intrathecally, into the cerebrospinal fluid, or locally to a site of inflammation.
14. The method of claim 1, wherein the MSCs are preconditioned with at least one of the following: hypoxia, hyperthermia, or co-cultured with immune cells to enhance tolerogenic properties prior to administration.
15. The method of claim 1, wherein the MSCs promote expansion of regulatory T cells and B cells, suppresses autoreactive T cells and Thl7 responses, and modulates antigen-presenting cell function.
16. The method of claim 1, wherein the pluripotent stem cells and MSCs are generated and cultured in xeno-free, feeder-free, chemically defined conditions and validated for pluripotency and safety (karyotype, teratoma assay, or gene expression).
17. The method of claim 1, wherein the cell population from the patient are autologous somatic cells, enabling personalized antigen-specific tolerance induction.Immorta-TOAUPMSC-PCT18. The method of claim 8, wherein the MSCs are engineered to home to lymphoid (issues or sites of inflammation via chemokine receptor expression and are encapsulated or delivered via hydrogel scaffolds.
19. The method of claim 1, wherein the MSCs express a suicide gene for controlled elimination and is tested for potency by in vitro suppression of pro-inflammatory cytokines or autoreactive immune responses.
20. Use of an autologous engineered mesenchymal stem cell, generated from patient-derived iPSCs expressing disease-specific autoantigens and tolerogenic molecules IL-27 and / or PD-L1, for the treatment of autoimmune disease by restoring anligcn-spccilic immune tolerance.
